ACoP2024

15TH ANNUAL AMERICAN CONFERENCE ON PHARMACOMETRICS

November 10 -13 | Arizona Grand Resort, Phoenix, Arizona

Past as Prologue.
Bridges to New Horizons

2024

Organized and sponsored by ISoP

DEAR COLLEAGUES

Welcome to ACoP2024 in Phoenix, Arizona!

We're excited to return to the state where it all began with our inaugural meeting in 2008 as we celebrate this milestone. This year's theme, ***"Past as Prologue. Bridges to New Horizons,"*** underscores our commitment to honoring our roots while charting new paths in Pharmacometrics.

ACoP2024 kicks off with an exciting pre-conference on Sunday, November 10, titled *"Exploring New Frontiers: Quantitative Pharmacology for Emerging Therapeutic Modalities."* This full-day session will dive into cutting-edge cell and gene therapies, siRNA therapies, bispecifics, ADCs, and more, capped with an interactive discussion on the challenges and opportunities in advancing these novel therapies.

We are honored to feature a *Keynote Address* from *Dr. Peter Stein* of the U.S. FDA and a *State-of-the-Art Lecture* by *Dr. Tawanda Gumbo* from the University of Cape Town. Our opening session on Sunday will present the *2024 ISoP Awards, the induction of ISoP Fellows,* and the *Lewis B. Sheiner Award lecture*, celebrating extraordinary contributions to the field of Pharmacometrics.

The program features:

- *15 Symposia*
- *6 "Birds of a Feather" Sessions*
- *3 Lunch & Learn Sessions*
- *20 Individual Talks*
- *2 Free Tutorials*
- *1 Trainee Tutorial*
- *10 Workshops*

Highlights include:

- *"The Future is Now: Envisioning the Next Era of Pharmacometrics"*
- *"Charting New Frontiers: CDER's Quantitative Medicine Center of Excellence"*
- *The ACoP2024 Quality & Trainee Awards*

Don't miss the ACoP2024 Crystal Ball on Monday night! To mark 15 years of ACoP, we invite you to dress in silver or sparkling attire, reflecting the bright and exciting future ahead. Enjoy an evening of mingling, dancing, and lawn games under the Arizona stars. Additional networking opportunities include Tuesday's *Happy Hour* and daily *Trivia Quest* on the ISoP app.

Take a *"Walk Down Memory Lane*" to explore ACoP's journey from 2008 to 2024 from your shared photos. Learn more about ISoP/ACoP's mission and history at the registration booth, and connect with us through *ISoP Connect* and the updated ISoP App. We extend our gratitude to the ACoP2024 Planning Committee, especially *Fiona Glassman, Jennifer Redmond, Barbara Mock,* and to our sponsors and exhibitors. Congratulations to the 2024 ISoP Fellows, Award Winners, and Quality and Trainee Award recipients.

Thank you for being part of ACoP2024. We look forward to a conference full of inspiration and valuable connections. For the latest updates, visit the *ACoP2024 website* and use the ***ISoP app.***

Enjoy the conference!

Wei Gao
Conference Chair

Emmanuel Chigutsa
Scientific Programming Chair

Vijay Ivaturi
President, ISoP



Get the app

Download on iOS or Android

1. Scan the QR code.

2. Install the free Eventscribe app.

3. Open the app and search for ACoP2024.

4. When prompted, log in using your Username and Password *(your Access Key)*.

ACOP2024 PLANNING COMMITTEE

Conference Chair
Wei Gao

Project Manager
Fiona Glassman

Pre Conference
Joy Hsu, Co-Chair
Mark Lovern, Co-Chair
Lourdes Cucurull-Sanchez, Chair-Elect

Scientific Programming
Emmanuel Chigutsa, Chair
James Lu, Chair-Elect
Curtis Johnston
So Miyoshi
Nastya Kassir
Bhargava Kandala
Wangda Zhou
Chiara Zecchin
Yi Ting (Kayla) Lien
Dongyang Liu
Jingqi Gong
Mikiko Nakamura
Florencio Serrano Castillo
Brian Cicali
Tongli Zhang
Hardik Chandasana
Ada Zhuang
Ye Xiong
Sean Avedissian
Anna Kondic
Neelima Thaneer

Abstract Committee
Wan Sun, Chair
Xiaowei Zang, Chair-Elect
Meenakshi Srinivasan
Abhinav Kurumaddali
Syed Zaidi
Abhigyan Ravula
Sven Mensing
Arya Pourzanjani
Jesmin Lohy Das
Yasong Lu
Stefanie Drescher
Steve Choy
Natalia de Moraes
Mita Kuchimanchi
Tao Niu
César Pichardo
Lucy Her
Phyllis Chan
Carl Panetta
Jing Su

Alumni Committee
Jingxian (JC) Chen, Chair
Satyawan B. Jadhav, Chair-Elect
Min Hai
Xiao Shelley Hu

Social
Hillary Husband, Co-Chair
Eric Salgado, Co-Chair
Estefany Garcia, Chair-Elect
Carol Conchon Costa
Rena Byrne
Jason Chittenden

Trainee
Sean McCann, Co-Chair
Yuhan Long, Co-Chair
Se Jin Kim
Jessica Barry
Bovornpat Suriyapakorn
Rachel Sousa
Alex Foster-Powell
Eun Seok Yang

Communication
Eleni Caratzas, Chair
Peter Bloomingdale, Chair-Elect
Fernando Carreno
Victor Ejigah
Philip Chang

ISoP Awards Committee
Nahor Haddish-Berhane, Chair
Yan Xu, Chair-Elect
Navin Goyal
Brenda Ciricione
Jason Chang
Lourdes Cucurull-Sanchez
Mathangi Gopalkrishnan
Bela Patel
Kimio Terao
Venkatesh Pilla Reddy
Chihiro Hasegawa
Francois Gaudreault
Christina Friedrich
Rajendra Singh
Pavan Vaddady
Catherine Weathered

ISoP Fellows Panel
Nahor Haddish-Berhane
Daniele Ouellet
Donald Mager
Justin Wilkins
Saroja Ramanujam
Lena Friberg
Robert Bies
Catherine Weathered

ISoP
Jennifer Monroy, ISoP Executive Director
Jennifer Redmond, ISoP Senior Assoc. Manager

Meeting Planner
Barbara Mock

Monday, November 11
7:15 pm - 11:00 pm, Canyon Ballrooom

Please join us at this year's main social event - the Crystal Ball! Celebrate 15 years of ACoP and the future of ISoP! We encourage everyone to come dressed in **metallic, sparkly, or iridescent attire.** Enjoy a fun-filled evening with a photo booth, lawn games, music, and, of course, plenty of dancing!

Trivia Quest: Test your knowledge of ACoP! **ACoP or ISoP Trivia** questions will be released on the app every morning. Check back at the end of the day for the answers and see if you're a winner!

Buddy System: First-time ACoP attendee? Get paired with an experienced attendee to help you navigate the conference. Meet and get to know your Buddy at the special **Buddy System Kickoff** on Sunday at 4:30 pm in Sonoran Sky Ballroom 1-3 (right before the opening session.) Connect again at Tuesday morning's coffee service, starting at 7:00 AM.

Happy Hour: Come join us from 3:30 – 5:00 PM Tuesday, November 12 at the **Poster Session!** Grab a drink at the cash bar, browse the posters, and engage with presenters!

AGENDA

SATURDAY NOVEMBER 9

Start	End		Vendor	
7:00 AM	8:00 AM	Registration – Pre-Workshop Attendees		Sonoran Sky Registration
8:00 AM	5:00 PM	Pre-Workshop – Scientific Modeling Augmented by Machine-Learning with DeepPumas	Pumas AI	Lantana Room
8:00 AM	5:00 PM	Pre-Workshop – Efficient reproducible Bayesian population PK modeling with NONMEM and Stan/Torsten	Metrum Research Group	Mesquite Room
8:00 AM	5:00 PM	Pre-Workshop – Hands-On Introduction to InSilicoTrials' Cloud-Based Clinical Trial Simulator	Insilico Trials	Kaibab Room
8:00 AM	5:00 PM	Pre-Workshop – New and Advanced Features of NONMEM 7.5 Workshop	ICON Clinical Research LLC	Noble Room
10:00 AM	10:30 AM	Coffee Break for ACoP Pre-Workshop Attendees		Sunset Patio
12:00 PM	1:00 PM	Lunch for ACoP Pre-Workshop Attendees		Sunset Patio
1:00 PM	5:00 PM	Pre-Workshop – Practical Tools for Model Calibration with SimBiology	MathWorks	Ocotillo B Room
3:00 PM	3:30 PM	Coffee Break for ACoP Pre-Workshop Attendees		Sunset Patio

SUNDAY NOVEMBER 10

Start	End	Event	Vendor / Speakers	Location
7:00 AM	8:00 AM	Registration – Workshop & Pre-Conference Attendees		Sonoran Sky Registration
8:00 AM	5:00 PM	Biologics (ADC) whole-body PBPK/QSP in PK-Sim and MoBi	ESQlabs GmbH	Kaibab
		Scientific Modeling Augmented by Machine-Learning with DeepPumas	PumasAI	Lantana
		Efficient reproducible Bayesian population PK modeling with NONMEM and Stan/Torsten	Metrum Research Group	Mesquite
		Simcyp Designer PBPK-QSP Focused Workshop	Certara	Noble
		Modeling Delays in Pharmacokinetics and Pharmacodynamics using Phoenix	ISoP MCS SIG	Palm 2A/B
8:00 AM	**4:45 PM**	**Pre-Conference – Exploring New Frontiers: Quantitative Pharmacology for Emerging Therapeutic Modalities**	**Chairs:** Joy C. Hsu, Genentech & Mark Lovern, Independent	Sonoran Sky Ballroom 4
10:00 AM	10:30 AM	Coffee Break – ACoP Workshop Attendees		Sunset Patio
10:15 AM	10:30 AM	Coffee Break – Pre-Conference Attendees		Sonoran Patio
11:45 AM	12:45 PM	Lunch & Posters – Pre-Conference Attendees		Sonoran Sky Ballroom 1-3
12:00 PM	1:00 PM	Lunch – ACoP Workshop Attendees		Sunset Patio
12:00 PM	7:30 PM	ACoP2024 Conference Registration		Sonoran Sky Registration
3:00 PM	3:30 PM	Coffee Break – ACoP Workshop Attendees		Sunset Patio
		Coffee Break – Pre-Conference Attendees		Sonoran Patio
4:45 PM	5:15 PM	ISoP Awards & Fellows Reception **(by invitation only)**		Palm 3 Patio
5:30 PM	**7:30 PM**	**ACoP2024 Opening Session:**		Canyon Ballroom
		Welcome / Conference Highlights	Wei Gao, Moderna	
		Presentation of ISoP Awards & Induction of Fellows	Nahor Haddish-Berhane, Janssen	
		Lewis B. Sheiner Award Lecture – "Pharmacometrics and Systems Pharmacology Research: A Pharmacist's Perspective"	Donald Mager, SUNY Buffalo	
7:30 PM	10:00 PM	Opening Welcome Reception		Arizona Grand Ballroom

THE INTERNATIONAL
SOCIETY OF PHARMACOMETRICS

PRESENTS

ACoP2024

OPENING SESSION & ISOP 2024 AWARDS CEREMONY

SUNDAY, NOVEMBER 10TH: CANYON BALLROOM

OPENING REMARKS: Wei Gao

AWARDS PRESENTATIONS: Nahor Haddish-Berhane

LEADERSHIP AWARD
RECIPIENT: **Mats Karlsson, Ph.D.**

ISoP OUTSTANDING RESEARCH MANUSCRIPT AWARD
RECIPIENT: **Monica Susilo, Ph.D., et al**
On behalf of all co-authors

UNSUNG HERO AWARD
RECIPIENT: **Eleni Caratzas, MSc, Ph.D.**

EMERGING SCIENTIST AWARD
RECIPIENT: **Thanaporn Wattanakul, Ph.D.**

INDUCTION OF 2024 ISOP FELLOWS INDUCTEES:
Ioannis (Yannis) P. Androulakis, Ph.D. & Chris Penland, Ph.D.

SHEINER AWARD & LECTURE
RECIPIENT: **Donald Mager, PharmD, Ph.D.**
Lecture: "Pharmacometrics and Systems Pharmacology Research: A Pharmacist's Perspective"

CLOSING REMARKS: Wei Gao

PLEASE JOIN US FOR THE
ACoP2024 OPENING RECEPTION in the Arizona Grand Ballroom

We request that all award winners remain until the close of the program for photos.

MONDAY NOVEMBER 11

Start	End	Event	Chair / Speakers	Location
7:00 AM	9:00 AM	Exhibits / Posters / Coffee Service		Arizona Grand Ballroom
7:00 AM	5:00 PM	Professional Headshot Booth Sponsored by AstraZeneca & Simulation Plus		Sonoran Sky Foyer
9:00 AM	9:45 AM	General Session - President's Address	Vijay Ivaturi, Pumas AI	Canyon Ballroom
9:45 AM	10:45 AM	State-of-the-Art Lecture	Tawanda Gumbo, MD, Professor of Medicine, University of Cape Town, South Africa	Canyon Ballroom
11:00 AM	**12:30 PM**	**Concurrent Session C1A - Quantitative Systems Pharmacology in Late-Stage Oncology Drug Development – New Horizons to Dose Optimization**	**Chairs:** Piet van der Graaf, Certara & Amitava Mitra, Kura Oncology	Canyon Ballroom
		Dose guidance for a novel combination therapy to treat head and neck squamous cell carcinoma (HNSCC) for patients with HRAS/PIK3CA variants using QSP model	Amitava Mitra, Kura Oncology	
		Model-based Dose Selection for Epcoritamab, a subcutaneous CD3xCD20 bispecific antibody	Tommy Li, Genmab	
		QSP Modeling and Dose Optimization: A Regulatory Perspective	Atiqur Rahman, FDA	
11:00 AM	**12:30 PM**	**Concurrent Session C1B - Intersecting Realities: Showcasing the Power of Imaging and Modeling in Biomedicine and Drug Development**	**Chairs:** Mirwais Wardak, Genentech & Owen Richfield, Yale University	Sonoran Sky Ballroom 1 - 4
		Image-Based Computational Fluid Dynamics Modeling of Inthrathecal Drug Delivery for CNS Diseases	Mirwais Wardak, Genentech	
		Positron Emission Tomography and Tracer Kinetic Modeling for Quantitative Molecular Imaging in Drug Discovery and Development	Marc D. Normandin, Yale University	
		Total-Body PET Kinetic Modeling and Its Potential Applications to Drug Development and Evaluation	Guobao Wang, University of California, Davis	
11:00 AM	**12:30 PM**	**Concurrent Session C1C - Modeling approaches in pregnancy and lactation for drug development: operational, ethical and regulatory perspectives**	**Chairs:** Karen Rowland Yeo, Certara UK Ltd & Priya Jayachandran, Regeneron	Sonoran Sky Ballroom 5 - 8
		Ethical and Operational Considerations for Clinical Study Design and Conduct in Neonatal & Pregnancy Research	Walter K. Kraft, Thomas Jefferson University	
		Bridging the Gap – Clinical Studies Supported by Modeling in a Community Setting	Catriona Waitt, University of Liverpool, UK and Infectious Diseases Institute, Makerere University, Uganda	

MONDAY NOVEMBER 11

Start	End	Event	Chair / Speakers	Location
11:00 AM	12:30 PM	Regulatory Experiences and Considerations for Model-Informed Approaches to Drug Development in Pregnancy and Lactation	Elimika Pfuma Fletcher, FDA	Sonoran Sky Ballroom 5 - 8
		Large language model and active learning guided pharmacology therapy knowledge gap discovery in maternal and pediatric patients	Lang Li, The Ohio State University	
		Modeling and simulation to support therapy in pregnancy and lactation	Sara Quinney, Indiana University School of Medicine	
		Panel Discussion	Walter K. Kraft, Thomas Jefferson University, Catriona Waitt, University of Liverpool, UK and Infectious Diseases Institute, Makerere University, Uganda, Elimika Pfuma Fletcher, FDA, Lang Li, The Ohio State University, Sara Quinney, Indiana University School of Medicine	
11:00 AM	**12:30 PM**	**Birds of a Feather 1 (BOAF1) - Overcoming the Challenges of Cancer Drug Resistance: Applying Evolutionary Principles from Bench to Bedside**	**Chair:** Yan Ji, Novartis & Molly Zhao, Gilead Sciences	Kaibab & Lantana
		Designing evolution-based treatment strategies based on the principles of convexity and concavity	Jeffrey West, H. Lee Moffitt Cancer Center & Research Institute	
		Evolutionary and spatiotemporal response dynamics in metastatic colorectal cancers	Yanguang Cao, University of North Carolina at Chapel Hill	
		Drug combinations paired with strategic scheduling: leveraging quantitative systems pharmacology to overcome drug resistance	Birgit Schoeberl, Novartis	
12:30 PM	2:00 PM	Exhibits / Posters		Arizona Grand Ballroom
		Lunch		Arizona Grand Ballroom & Palm Court
		Trainee Lunch		Mesquite & Noble
12:30 PM	**2:00 PM**	**Lunch & Learn - Standardization and Best Practices as Bridges to the Future: Securing the Foundation for Growth of Model-Informed Drug Development**	**Chair:** Wonkyung Byon, Vertex & Shelly Wang, Gilead Sciences	Palm 3 A/B
		Pharmacometrics Workflow: Points to Consider for Efficient, High-Quality, and Reproducible Analyses	Jace Nielsen, Astellas	

MONDAY NOVEMBER 11

Start	End	Event	Chair / Speakers	Location
		How to Implement CDISC data standards for Population PK Analysis in your organization	Neelima Thanneer, BMS	Palm 3 A/B
		Working towards a standardized population PK/PD reporting template for the industry	Yali Liang, Jazz Pharmaceuticals	
12:30 PM	2:00 PM	JPKPD Meeting **(by invitation only)**		Palm 2 A/B
2:00 PM	**3:00 PM**	**Special Session – "The Future is Now: Envisioning the Next Era of Pharmacometrics"**	**Chairs:** Lora Hamuro, BMS & Stephen Greene, Rappor TRX **Panelist:** Hao Zhu, ISoP, Liang Zhao, USCF, C.J. Musante, Pfizer, Mark Dresser, Gilead Sciences	Canyon Ballroom
3:00 PM	3:15 PM	Coffee Break		Canyon Ballroom Patio & Sonoran Patio
3:15 PM	**4:45 PM**	**Concurrent Session C2A - Enabling Progress Against Alzheimer's Disease: Power of Diverse Pharmacometrics Approaches**	**Chairs:** Julie A. Stone, Merck & Youfang Cao, Eisai	Canyon Ballroom
		Pharmacometrics for the Win: How Modeling Helps Demonstrate Efficacy in Alzheimer's Disease and Provides Insight into Drug Activity	Brian A. Willis, Biogen	
		Model Informed Drug Development (MIDD) in Alzheimer's Disease	Ivelina Gueorguieva, Eli Lilly and Company	
		Mapping Longitudinal Biomarker Relationships in Alzheimer's Disease with Latent Time Joint Mixed Effects Modeling	Seth Robey, Merck	
		Panel Discussion	Julie A. Stone, Merck, Youfang Cao, Eisai, Brian A. Willis, Biogen, Ivelina Gueorguieva, Eli Lilly & Company, Seth Robey, Merck, Stephen Duffull, Certara	
3:15 PM	**4:45 PM**	**Concurrent Session C2B - Mind the gap – successful bridging of QSP and PMX in drug development**	**Chairs:** Georgi Kapitanov, Certara / Applied BioMath & Amita Joshi, Genentech	Sonoran Sky Ballroom 1 - 4
		Joined PMX and QSP modeling to guide step-up dosing of a bispecific antibody for prostate cancer	Mirjam Trame, Certara	
		Convergence of QSP and Pharmacometrics – Are we there yet?	Kapil Gadkar, Genentech	
		The best of both worlds? Integration of QSP and PMx modeling in support of MIDD in oncology	Blerta Shtylla, Pfizer R&D	

MONDAY NOVEMBER 11

Start	End	Event	Chair / Speakers	Location
3:15 PM	4:45 PM	Panel Discussion	Amita Joshi, Genentech, Mirjam Trame, Certara Blerta Shtylla, Pfizer, Kapil Gadkar, Genentech C.J. Musante, Pfizer, Jin Jin, Genentech	Sonoran Sky Ballroom 1 - 4
3:15 PM	**4:45 PM**	**Concurrent Session C2C - Integration of modelling, endogenous biomarkers, and real-world study approaches to support precision dosing in special populations**	**Chairs:** Dongyang Liu, Peking University Third Hospital & Aleksandra Galetin, University of Manchester	Sonoran Sky Ballroom 5 - 8
		The current clinical needs and gaps for precision medicine of special populations	Dongyang Liu, Peking University Third Hospital	
		Estimation of FMO3 Ontogeny by Mechanistic Population Pharmacokinetic Modelling of Risdiplam and Its Impact on Drug–Drug Interactions in Children	Michael Gertz, F. Hoffmann-La Roche Ltd	
		Application of endogenous biomarkers of drug transporters and liquid biopsy coupled with PBPK modelling to support precision dosing in renal impairment	Aleksandra Galetin, University of Manchester	
		Utilization of Real-World Data in Clinical Pharmacology – Regulatory Perspectives	Lixia Zhang, FDA	
3:15 PM	**4:45 PM**	**Birds of a Feather 2 (BOAF2) - Harnessing Efficiency in Quantitative Systems Pharmacology (QSP) Modeling: Integrating Workflows, Automation, and Visualization Tools for Enhanced Cross-Functional Communication**	**Chairs:** Alice Zong, Johnson & Johnson & Rajat Desikan, GSK	Kaibab & Lantana
		A streamlined QSP workflow for digital-twin enabled in silico trials with chronic Hepatitis B infection	Rajat Desikan, GSK	
		A streamlined communication framework needed for unleashing the power of QSP-informed drug development	Jane PF Bai, FDA	
		Thales: A unified framework for clinical-scale QSP modeling	Ryan Suderman, Simulations Plus, Inc.	
		Panel Discussion	Rajat Desikan, GSK, Jane PF Bai, FDA, Ryan Suderman, Simulation Plus, Corey J. Bishop, Johnson & Johnson	
5:00 PM	6:30 PM	Communication Challenge: ISoP Trainee Talks		Sonoran Sky Ballroom 1 - 4

MONDAY NOVEMBER 11

Start	End	Event	Chair / Speakers	Location
5:00 PM	6:30 PM	QSP SIG Event: Strategies for Successful Application of QSP Platform Models for Clinical Development and Regulatory Engagement	**Chairs:** Steve Change, Simulations Plus, Weirong Wang, Johnson & Johnson, Brian Schmidt, BMS	Sonoran Sky Ballroom 5 - 8
		Case application vignettes of QSP platform models informed by clinical data	Mengdi Tao, Sanofi, Alex Ratushny, BMS, Rohit Rao, Pfizer, Iraj Hosseini, Genentech	
		Panel Discussion	Richard Allen, Pfizer, Brian Schmidt, BMS, Bill Macias, Immunovant, Jin Jin, Genentech, Lourdes Cucurull-Sanchez, GSK, Susana Zaph, Sanofi	
7:15 PM	11:00 PM	Social Dinner Event		Canyon Ballroom

TUESDAY NOVEMBER 12

Start	End	Event	Chair / Speakers	Location
7:00 AM	9:00 AM	Exhibits / Posters / Coffee Service		Arizona Grand Ballroom
7:00 AM	5:00 PM	Professional Headshot Booth Sponsored by AstraZeneca & Simulation Plus		Sonoran Sky Foyer
8:30 AM	9:00 AM	In Memoriam: Dr. Thomas M. Ludden	**Speakers:** Steve Riley, Pfizer, Jae Eun Ahn, Pfizer, Bob Bauer, ICON	Sonoran Sky Ballroom 1 - 4
9:00 AM	**10:15 AM**	**General Session - Keynote Speaker**	Peter Stein M.D. Director, Office of New Drugs Center for Drug Evaluation and Research the US Food and Drug Administration	Canyon Ballroom
10:15 AM	11:15 AM	Fireside Chat - Charting New Frontiers: CDER's Quantitative Medicine Center of Excellence	**Chair:** Wei Gao, Moderna **Speakers:** Rajanikanth Madabushi, FDA, Hao Zhu, ISoP, Robert Lionberger, FDA, Peter Stein, FDA	Canyon Ballroom

TUESDAY NOVEMBER 12

Start	End	Event	Chair / Speakers	Location
11:15 AM	12:30 PM	Presentation of the Abstract Quality & Trainee Awards	Wan Sun, Vertex	Canyon Ballroom
12:30 PM	2:00 PM	Exhibits / Posters		Arizona Grand Ballroom
		Lunch		Arizona Grand Ballroom
		SIG Lunch – Programming - Embracing modern programming tools for pharmaco-metrics (PMx) dataset creation, review and reporting	**Chairs:** Jing Su, Neelima Thanneer, BMS **Speakers:** Neelima Thanneer, BMS, Xiaobin Li, GSK, Alice Zong, J&J	Palm 3C
		SIG Lunch – Clinical Pharmacometrics		Palms 3 A/B
		SIG Lunch – MCS		Mesquite & Noble
2:00 PM	**3:30 PM**	**Concurrent Session C3A - Visionary Analytics: Advancing Ophthalmology with historical insights and advanced modeling methodologies**	**Chairs:** Joy C. Hsu, Genentech, Hao Zhu, ISoP	Canyon Ballroom
		Bridging new horizons for ophthalmology: State of the art methodologies and outlook	Joy C. Hsu, Genentech	
		Historical borrowing in nAMD: the present as a "prior" for designing more efficient future trials	Francesco Brizzi, Roche Pharma	
		Charting New Paths in Ophthalmology with DeepNLME-Powered Predictive Modeling	Niklas Korsbo, Pumas-AI	
		Panel Discussion	Joy C. Hsu, Genentech, Hao Zhu, ISoP, Francesco Brizzi, Roche Pharma, Niklas Korsbo, Pumas-AI	
2:00 PM	**3:30 PM**	**Concurrent Session C3B - Leveraging quantitative models to design and develop the next generation of multi-specific T-Cell engager molecules**	**Chairs:** Isabel M. Figueroa, Gilead & Iraj Hosseini, Genentech	Sonoran Sky Ballroom 1 - 4
		Development of a Quantitative Systems Pharmacology Model to Support the Clinical Development of T cell Redirecting Bi- and Tri-specific Antibodies for Patients with Relapsed/Refractory Multiple Myeloma	Jin Niu, J&J	
		Utilizing platform QSP models for later phase trial design and dose selection	Brian Schmidt, BMS	
		Bispecific T-cell engagers: From receptor to systems' level modeling to rationalize dose-effect relationships	Alexander Kulesza, esqLABS	

TUESDAY NOVEMBER 12

Start	End	Event	Chair / Speakers	Location
2:00 PM	**3:30 PM**	**Concurrent Session C3C - Next generation M&S packages deployable and accessible for MIDD and Model Integrated Evidence - Advances Through GDUFA-Sponsored Research**	**Chairs:** Yuqing Gong, FDA & Robert R. Bies, University at Buffalo	Sonoran Sky Ballroom 5 - 8
		User-Friendly Tools for Population PK and PBPK Modeling	Robert R. Bies, University at Buffalo	
		Development of A User-Friendly Platform for Model-Integrated Bioequivalence Analysis	Andrew C. Hooker, Uppsala University	
		Advancing Artificial Intelligence (AI) tools for drug R&D	Liang Zhao, UCSF	
2:00 PM	**3:30 PM**	**Birds of a Feather 3 (BOAF3) - Advancing QSP: From Virtual Patient To Digital Twin**	**Chairs:** Jingqi Gong, GlaxoSmithKline & Richard Allen, Pfizer	Kaibab & Lantana
		Does the Why Lead to the How to Build Virtual Populations?	Richard Allen, Pfizer	
		QSP modeling of engineered autologous T-cell therapies: random virtual patients vs virtual twins	Oleg Demin Jr., InSysBio CY	
		The Use of Quantitative Systems Pharma-cology-based Digital Twins to Support Drug Development in Rare Diseases	Susana Zaph, Sanofi	
		Panel Discussion	Jingqi Gong, GSK, Oleg Demin Jr., InSysBio CY, Richard Allen, Pfizer, Susana Zaph, Sanofi	
3:30 PM	5:00 PM	Exhibits / Posters / Happy Hour		Arizona Grand Ballroom
5:00 PM	6:00 PM	University Receptions		
		University at Buffalo Reception		Palms 3C
		University of Florida Reception		Palms 3D
		University of Maryland Reception		Palms 3A
		University of Minnesota Reception		Palms 3B
		University of North Carolina Reception		Palms 2A/B
		University of Tennessee Reception		Ocotillo A
6:00 PM	7:30 PM	President's Reception **(by invitation only)**		Vista Room

WEDNESDAY NOVEMBER 13

Start	End	Event	Chair / Speakers	Location
7:00 AM	9:00 AM	Exhibits / Posters / Coffee Service		Arizona Grand Ballroom
9:00 AM	**10:30 AM**	**Concurrent Session C4A - What is the future and impact of artificial intelligence and machine learning (AI/ML) in each SIGs**	Luke Fostvedt, Pfizer on behalf of the xSIG Leadership Team	Canyon Ballroom
		Use of AI/ML to Support New Drug Development and Enhance Patient Care	Hao Zhu, ISoP	
		QSP in the era of ML	Ioannis (Yannis) Androulakis, Rutgers University	
		Using machine learning and multiomics to predict the pharmacokinetics of immunosuppressants and clinical outcomes in renal transplant patients	Hao-Jie Zhu, University of Michigan College of Pharmacy	
		Panel Discussion	Hao Zhu, ISoP, Hao-Jie Zhu, University of Michigan College of Pharmacy, Limei Cheng, Lourdes Cucurull-Sanchez, GSK, Yuan Xiong, Johnson & Johnson, Neelima Thanneer, BMS	
9:00 AM	**10:30 AM**	**Concurrent Session C4B - Challenges in characterizing treatment response in oncology - Pitfalls and solutions**	**Chairs**: Martin Bergstrand, Pharmetheus AB, Pavan Vaddady, Merck & Co.	Sonoran Sky Ballroom 1 - 4
		Dose Selection and Optimization in Oncology: Focus on ADCs	Tushar Garimella, Daiichi Sankyo Inc	
		The flawed assumption of proportional hazards in oncology studies - What are the alternatives?	Andrew C. Hooker, Uppsala University	
		Joint modeling of longitudinal biomarker data and progression free survival to accelerate drug approvals in oncology	Antoine Pitoy, INSERM / Université Paris Cité	
9:00 AM	**10:30 AM**	**Concurrent Session C4C - Decoding the Past, Crafting the Future: Unraveling the Role of Confounding in Exposure-Response Relationships for Small and Large Molecules**	**Chair:** David C. Turner, Genentech & Yulia Vugmeyster, EMD Serono	Sonoran Sky Ballroom 5 - 8
		Mechanisms that drive E-R confounding for large and small molecules: do we need to understand these to address E-R confounding in our analyses?	Mitch Phelps, The Ohio State University	
		Exposure, response, and baseline-factor triangle for large and small molecules: a search for the right angle	Yulia Vugmeyster, EMD Serono	

WEDNESDAY NOVEMBER 13

Start	End	Event	Chair / Speakers	Location
		Untangling Cause-and-Effect for Oncology Dose Selection: Exposure-Response Confounding with Small Molecules	Youwei Bi, FDA	Sonoran Sky Ballroom 5 - 8
9:00 AM	**10:30 AM**	**Birds of a Feather 4 (BOAF4) - Opening New Frontiers in Pharmacometrics & QSP Modeling: Leveraging Physics- and Pharmacology-informed Neural Networks**	**Chairs:** James Lu, Genentech, Diansong Zhou, AstraZeneca	Kaibab & Lantana
		Merging Multimodal with Longitudinal data: Leveraging Graph Neural Networks and Neural-ODEs	James Lu, Genentech	
		Pharmacometrics Modeling via Physics-Informed Neural Networks: Integrating Time-Variant Absorption Rates and Fractional Calculus for Enhancing Prediction Accuracy	Nazanin Ahmadi Daryakenari, Brown University	
		Machine Learning for Developing Interpretable Population PK Models	Damilola O. Olabode, AstraZeneca	
10:30 AM	10:45 AM	Coffee Break		Canyon Ballroom Patio & Sonoran Patio
10:45 AM	**12:15 PM**	**Roller Coaster 1**	**Moderator:** Emmanuel Chigutsa, Eli Lilly and Company	Canyon Ballroom
		Use of quantitative tools to facilitate TCE development—CRS and beyond	Xiling Jiang, FDA	
		Transforming Healthcare with Large Language Models: Opportunities and challenges	Joga Gobburu, University of Maryland	
		Opportunities between ASA BioPharm and ISOP: Training the next generation Quantitative Scientists	Theodore Lystig, BridgeBio	
		Optimizing Dosing and Efficiency in Developing Direct Oral Anticoagulants Through Modeling-Informed Approaches	Liping Zhang, Johnson & Johnson	
		Bridging to New Horizons in Pharmacometrics and Drug Development through Digital Health Innovation	Grace V. Lee, Critical Path Institute	
10:45 AM	**12:15 PM**	**Roller Coaster 2**	**Moderator:** Fiona Glassman, Biogen	Sonoran Sky Ballroom 1-4
		Decoding complex drug-drug-renal disease interaction mediated by hepatic enzymes and transporters using PBPK approach	Jin Dong, AstraZeneca	
		Hitting the Sweet Spot: Mechanism-Based Modeling to Evaluate the Interplay of Liver Compound Exposure and Liver Toxicity to Identify Safe Dosing Regimens	Lisl Shoda, Simulations Plus, Inc	

WEDNESDAY NOVEMBER 13				
Start	End	Event	Chair / Speakers	Location
10:45 AM	12:15 PM	Validating QSP Models with Finesse: Elevating Performance through Biologically Anchored Precision	Fulya Akpinar Singh, Genmab	
		Quantitative Systems Pharmacology Modeling to Inform Preclinical-to-Clinical Translation of T-cell Engager Programs	Colin W. Castleberry, Amgen	Sonoran Sky Ballroom 1-4
		Integrated Microphysiological System and PBPK Modeling for Prediction of Human Diclofenac Pharmacokinetics	Suein Choi, Catholic University of Korea	
10:45 AM	**12:15 PM**	**Roller Coaster 3**	**Moderator:** Navin Goyal, Johnson & Johnson	Sonoran Sky Ballroom 5 - 8
		Advancing Drug Development through Model Informed Drug Development: Insights from the ICH M15 MIDD Guidance Working Group	Jenny Chien, Eli Lilly and Company	
		Overadjustment bias and mediation analysis in PK/PD modeling	Sebastiaan C. Goulooze, LAP&P Consultants BV	
		MIDD in the clinical development of gene therapy: from bench to bedside	Eleni Caratzas, Janssen	
		Breaking down barriers within and across disciplines: the power of data integration	Stephan Schmidt, University of Florida	
		Power Determination During Drug Development: Is Optimizing the Sample Size Based on Exposure- Response Analyses Underutilized?	Ahmed H. Salem, Abbvie	
10:45 AM	**12:15 PM**	**Roller Coaster 4 - Birds of a Feather 5 (BOAF5)**	**Moderator:** Annie Lumen, Amgen	Kaibab & Lantana
		Mechanistic physiologically-based pharmacokinetic models for optimal development of bi-specific T cell engagers	Xinwen Zhang, Amgen	
		A mechanistic model to inform step-up dosing that limits cytokine release following a bispecific T cell engaging antibody treatment for B-cell lymphomas	Erik Welf, Regeneron	
		Fludarabine Therapeutic Drug Monitoring in Lymphodepletion Therapy for Pediatric CAR T-cell therapy	John C. Panetta, St. Jude Children's Research Hospital	
		The Future of Pharmacokinetics: Digital Twins and OoC in Harmony	Wilhelmus E.A. De Witte, ESQlabs	
		Weight Loss and Nausea from Subcutaneous and Oral Semaglutide Accurately Simulated with a QSP Model	Zackary R. Kenz, Simulations Plus	
12:15 PM	1:45 PM	Exhibits / Posters		Arizona Grand Ballroom

WEDNESDAY NOVEMBER 13				
Start	End	Event	Chair / Speakers	Location
12:15 PM	1:45 PM	Lunch		Arizona Grand Ballroom
		SIG Lunch - SXP		Palms 3 C/D
		SIG Lunch - QSP		Mesquite & Noble
12:15 PM	**1:45 PM**	**Lunch & Learn - Building high performing teams to influence decisions in drug development**	**Chair:** Enoch Cobbina, Syndax Pharmaceuticals	Palm 3 A
		Diversity and management of differences. Group-decision making and the role of psychological safety in effective decision making	Enoch Cobbina, Syndax Pharmaceuticals	
		Leveraging effective communication skills to deliver complex pharmacometrics results to non-pharmacometricians	Paolo Vicini, Confo Therapeutics	
1:45 PM	**3:15 PM**	**Concurrent Session C5A - Quantitative clinical pharmacology of antibody drug conjugate development: challenges and opportunities**	**Chairs:** Yan Feng, Genmab & Shelly Wang, Gilead Sciences	Canyon Ballroom
		Mechanistic QSP modeling for a deeper understanding of ADC toxicities and combination effects with immunotherapies	Katharina Wilkins, Metrum Research Group	
		Dose Optimization of ADCs	Rudy Gunawan, Pfizer	
		Regulatory Experiences and Considerations for Model-Informed Approaches in Antibody-drug conjugates (ADCs) Drug Development	Yangbing Li, FDA	
1:45 PM	**3:15 PM**	**Concurrent Session C5B - The Practical Bayesian: How Bayesian Methodology is Incorporated into Clinical Drug Development**	**Chairs:** Jiawei Zhou, Pfizer & Luke Fostvedt, Pfizer	Sonoran Sky Ballroom 1-4
		Hybrid Approaches in Pharmacometric Modeling: Integrating Maximum Likelihood and Bayesian Estimation	Timothy Waterhouse, Metrum Research Group	
		Parameter Selection and Uncertainty Quantification Techniques for Pharmacokinetic Models	Ralph Smith, North Carolina State University	
		Applying Bayesian Methods for Dose Optimization in Pediatric Oncology: Leveraging from Adult Population Pharmacokinetics	Nastya Kassir, Genentech	
1:45 PM	**3:15 PM**	**Concurrent Session C5C - Deep Learning in PKPD and Pharmacometrics: Diversity of Approaches and Applications**	**Chair:** Sean Hayes, Merck	Sonoran Sky Ballroom 5 - 8

WEDNESDAY NOVEMBER 13

Start	End	Event	Chair / Speakers	Location
1:45 PM	3:15 PM	Protein Language Models to incorporate PKPD considerations in early antibody design and generation	Louis Joslyn, Genentech	Sonoran Sky Ballroom 5 - 8
		Towards Generalizability of Neural ODEs in predictive applications in pharmacometrics	Sean Hayes, Merck	
		Integration of Graph Neural Network and Neural-ODEs for Tumor Dynamic Prediction	Omid Bazgir, Genentech	
1:45 PM	**3:15 PM**	**Birds of a Feather 6 - BOAF6 - Is Pharmaco-metrics limited by the industry settings?**	**Chairs**: Nieves Velez de Mendizabal, Eli Lilly and Company & Stacey Tannenbaum, Metrum Research Group	Kaibab & Lantana
		Panel Discussion	Ana Ruiz, Gilead Sciences, Julia Korell, Boehringer Ingelheim, Gemma Dickinson, Eli Lilly and Company, Joga Gobburu, University of Maryland, Peter Bonate, Astellas	
3:30 PM	4:00 PM	Closing General Session	Wei Gao, Moderna	Canyon Ballroom
4:30 PM	6:00 PM	ACoP2024 Meets ACoP 2025 **(by invitation only)**		Palms 3 C/D

THURSDAY NOVEMBER 14

Start	End	Event	Chair / Speakers	Location
7:00 AM	8:00 AM	Coffee Service – Tutorial Attendees		Arizona Grand Ballroom
8:00 AM	**12:00 PM**	**Tutorial 1 - Using Past Models to Bridge to Open Models and Open Science using nlmixr2**	**Chair:** Matthew L. Fidler, Novartis **Speakers:** William S Denney, Human Predictions, Mirjam Trame, Certara, Justin J. Wilkins, Occams	Sonoran Sky Ballroom 1 - 4
8:00 AM	**12:00 PM**	**Tutorial 2 - Model-Based Meta-Analysis: towards more precisely predicted clinical scenarios**	**Chairs:** Monica Simeoni, GSK & Phyllis Chan, Genentech **Speakers:** Matthew L. Zierhut, Certara, Rana Jreich, Sanofi, Elyes Dahmane, FDA, Joseph Chen, Genentech	Sonoran Sky Ballroom 5 - 8

THURSDAY NOVEMBER 14

Start	End	Event	Chair / Speakers	Location
9:00 AM	**12:00 PM**	**Tutorial – Trainee - Minimal PBPK Modeling: Tutorial and Applications**	**Chair:** Sean McCann, University of North Carolina & Yuhan Long, University of Minnesota **Speakers:** Yanguang Cao, University of North Carolina at Chapel Hill, Xiaonan Li, Takeda Pharmaceuticals, Dongfen Yuan, Janssen	Palms 3 C/D
10:15 AM	10:30 AM	Coffee Break – Tutorial Attendees		Sonoran Sky Patio & Palm 3 Patio
12:00 PM	1:00 PM	Registration & Lunch for ACoP Post-Workshop Attendees		Grand Veranda
1:00 PM	5:00 PM	Post Workshop – (R)TTE analysis: MIDD applications, concept, methodology and NONMEM hands-on	Pharmetheus	Sierra 2
1:00 PM	5:00 PM	LAP&P course: An interactive translational pharmacometric case study for an antibody exhibiting TMDD	LAP&P Consultants BV	Ocotillo A
3:00 PM	3:15 PM	Coffee Break for Post ACoP Workshop Attendees		Grand Veranda

FRIDAY NOVEMBER 15

Start	End	Event	Vendors	Location
8:00 AM	5:00 PM	Post Workshop – (R)TTE analysis: MIDD applications, concept, methodology and NONMEM hands-on	Pharmetheus	Sierra 2
8:00 AM	5:00 PM	Post Workshop – PBBM - Formulation development and virtual Bioequivalence	ESQlabs GmBH	Sierra 3
10:00 AM	10:30 AM	Coffee Break for Workshop Attendees		Grand Veranda
12:00 PM	1:00 PM	Lunch for ACoP Post-Workshop Attendees		Grand Veranda
3:00 PM	3:30 PM	Coffee Break for Workshop Attendees		Grand Veranda

Updates and schedule changes are available on the ACoP2024 App and ACoP website.

PETER STEIN, M.D.

Director, Office of New Drugs
Center for Drug Evaluation
And Research
the US Food and Drug Administration

Peter Stein, M.D., is the Director of CDER's Office of New Drugs (OND). OND is responsible for the regulatory oversight of investigational studies during drug development and decisions regarding marketing approval for new (innovator or non-generic) drugs, including decisions related to changes to already marketed products. OND provides guidance to regulated industry on a wide variety of clinical, scientific, and regulatory matters.

A nationally recognized leader in pharmaceutical research and development, Dr. Stein joined CDER in 2016 as the OND Deputy Director. Before coming to FDA, he served as Vice President for late stage development, diabetes, and endocrinology at Merck Research Laboratories. He also served as Vice President, head of metabolism development at Janssen. He has more than 30 years of academic, clinical, and industry experience.

Dr. Stein holds a bachelor's degree in history from the University of Rochester in New York and a medical degree from University of Pennsylvania. He trained at Yale University and Yale-New Haven Hospital in internal medicine and in endocrinology and metabolism.

DR. TAWANDA GUMBO, M.D.

Professor of Medicine, University of Cape Town, South Africa.

Dr. Tawanda Gumbo, MD, is Professor of Medicine at the University of Cape Town, South Africa, and he previously served as Professor at Baylor University Medical Center and the University of Texas Southwestern Medical Center. He graduated from the University of Zimbabwe Medical School, completed his Internal Medicine Residency at Case Western Reserve University, and Infectious Diseases Fellowship at the Cleveland Clinic in Ohio. Dr. Gumbo pioneered preclinical and clinical laboratory systems for various infections, immune responses, and cancer, integrating AI algorithms since 2006. He developed mathematical models for therapeutics, disease progression, and immune profiling. Gumbo was named to a World Health Organization (WHO) task force on pharmacokinetics and pharmacodynamics of tuberculosis (TB) medicines in 2017. His groundbreaking work has secured continuous funding from NIH and other sources, earning him multiple awards. Notably, his research optimized treatments for fungal and TB infections, and identified inhibitors for critical physiological pathways. Holding patents for diagnostics and monoclonal antibodies, Dr. Gumbo is also a published poet and novelist. His contributions extend to seminal chapters in pharmacology texts, including Goodman & Gilman's, and he has authored over 200 scientific publications.

2024 ★ AWARD WINNER

DON MAGER, PharmD, Ph.D.

Sheiner Award & Lecture

LECTURE:

"Pharmacometrics and Systems Pharmacology Research: A Pharmacist's Perspective"

Dr. Mager is Professor and Chair of Pharmaceutical Sciences at the University at Buffalo, State University of New York. He is also President and CEO of Enhanced Pharmacodynamics, LLC. He has served on the Pharmaceutical Sciences and Clinical Pharmacology Advisory Committee to the FDA and as a Visiting Professor at the University of Paris. He is a Fellow and Past-President of the International Society of Pharmacometrics and the American College of Clinical Pharmacology. Dr. Mager is also a Fellow of AAAS, AAPS, and FIP, the latter of which he serves as a Vice President via the Board of Pharmaceutical Sciences. He is also a member of the Scientific Advisory Board to Simcyp. Dr. Mager is well-known for his contributions on theoretical concepts and models for target-mediated drug disposition, signal transduction, and combinatorial therapeutics, with a focus on anti-cancer and immunomodulatory agents. Current research efforts seek to combine network-based analysis with empirical, systems, and machine-learning models to explore anti-cancer drug regimens, heterogeneity in cancer and other therapeutic responses, and chemotherapy-induced adverse effects. He served as a Co-Editor of the book Systems Pharmacology and Pharmacodynamics and has contributed to 180+ peer-reviewed publications and book chapters. He is co-founder of Truvai Biosciences, LLC.

2024 ★ AWARD WINNER

MATS KARLSSON, Ph.D.

Leadership Award

Mats Karlsson is a pharmacist with a Ph.D. in pharmacokinetics. Following postdocs at University of Glasgow and UCSF, he formed the pharmacometrics research group at Uppsala University, Sweden. In 2001, he was appointed Professor of Pharmacometrics, the first in the world. The model building research in his group has focused on new model types, modeling strategies and diagnostics. Many of the new methods have been implemented in open source software such as Xpose, PsN and Pharmpy. The methodology research has also focused on informing decisions, such as study designs and dose individualization. Therapeutic area-specific research has focused on concept models in oncology, infectious diseases, endocrinology, neurology, cardiovascular and respiratory diseases.
here has been a strong focus of education and competence building for the field and from the group >70 Ph.D.s has graduated, >50 postdocs have been mentored and it counts 10 full professors among its present or past members. Since 2011 he has organized the Uppsala Pharmacometric Summer School for international Ph.D. students. He has published >400 research articles in the pharmacometrics field and received awards and honors from ISoP, ACCP, ASCPT, BCPT, EUFEPS, PKUK and the Universities of Buffalo and Uppsala. In 2012, he co-founded the company Pharmetheus.

2024 ★ AWARD WINNER

MONICA SUSILO, PH.D., ET AL

On behalf of all co-authors

ISoP Outstanding Research Manuscript Award

Systems-based digital twins to help characterize clinical dose-response and propose predictive biomarkers in a Phase 1 study of bispecific antibody, mosunetuzumab, in NHL.

2024 ★ AWARD WINNER

THANAPORN WATTANAKUL, Ph.D.

Emerging Scientist Award

Dr. Wattanakul is an experienced pharmacometrician and licensed pharmacist with extensive proficiency in tropical diseases, particularly malaria. She holds a DPhil in Clinical Medicine from the University of Oxford, where she focused on the population pharmacokinetics and pharmacodynamics of antimalarial drugs. Currently, she serves as the Deputy Head of the Pharmacometrics Group at the Department of Clinical Pharmacology, Mahidol Oxford Tropical Medicine Research Unit.
In 2024, Dr. Wattanakul was selected to join the MORU-OUCRU Discovery Research Academy (MODRA), a Wellcome-funded program aimed at empowering early to mid-career researchers in South Asia to conduct impactful research in global health and infectious diseases. She also received the Young Investigator Award from the Joint International Tropical Medicine Meeting (JITMM) in 2023. Dr. Wattanakul's research aims to integrate pharmacometrics with multidisciplinary approaches to optimize treatment strategies for infectious diseases in low- and middle-income countries, providing valuable insights to inform health policy and improve patient outcomes.

2024 ★ AWARD WINNER

ELENI CARATZAS, MSc, Ph.D.

ISoP Unsung Hero Award

Eleni Caratzas (Karatza), MSc, Ph.D., is a Principal Scientist at J&J IM/ Janssen R&D. She completed her undergraduate and master's degrees in pharmacy at the University of Athens, Greece. Following her studies, she started working as a scientist-consultant at a pharmaceutical consulting firm. In 2017, she began her doctoral research at the University of Athens and a few years later she joined the Institute of Applied and Computational Mathematics in Crete, Greece as an affiliated researcher. After earning her Ph.D., she started her postdoctoral fellowship with the UNC Eshelman School of Pharmacy and GSK. Her work was recognized in 2020 when she was selected for the Lewis Sheiner student session by the PAGE organizing committee. She also participated as a panelist in the "Artificial Intelligence: Promises and Threats" session at the 70th Lindau Nobel Laureate Meeting. Dr. Karatza has published over 25 peer-reviewed articles and book chapters in the field of clinical pharmacology and pharmacometrics. An active ISoP member since 2018, she has supported various ISoP and ACoP initiatives. She has reviewed abstracts, hosted symposia, facilitated the ACoP app development, contributed to the ISoP newsletter and participated in ACoP's organizing committee by chairing the communications committee. She worked for the ISoP's influence and education working groups, supporting various activities to help knowledge dissemination and connectivity between pharmacometricians across the globe.

ISOP FELLOWS

Ioannis P. Androulakis
Jeffrey Barrett
Robert Bies
Peter Bonet
Richard Brundage
Rene Bruno
Brian Corrigan
David D'Argenio
Stephen Duffull
Jill Fiedler-Kelly
Jonathan French
Lena Friberg
Marc Gastonguay
Joga Gobburu
Nick Holford
Jin Y. Jin
Siv Jonsson
William Jusko
Mats Karlsson
Wojciech Krzyzanski
Donald Mager
France Mentre
Raymond Miller
Daniele Ouellet
Chris Penland
Marc Pfister
Saroja Ramanujan
Matthew Riggs
Stacey Tannenbaum
Yaning Wang
Justin Wilkins

PAST AWARD WINNERS

	Lewis B. Sheiner Lecture Award	ISoP Leadership Award	ISoP Innovation Award
2023	Joga Gobburu	Jin Y. Jin	Saroja Ramanujan
2022	Diane Mould	Mark R. Gastonguay	Admin Rosami Hodjegan & Geoffrey Tucker
2021	William Gillespie	Piet van der Graaf	Kyle Baron
2020	Elizabeth CM de Lange	Daniele Ouellet	Rene Bruno & Laurent Claret
2019	William J. Jusko	Brian Corrigan	Matthew Riggs & Mark Peterson
2018	David D'Argenio	Stacey Tannenbaum	Wenping Wang
2017	Marc Gastonguay	Rik Schoemaker	Donald Mager
2016	Alan Forrest	Sandy Allerheiligen	Lena Friberg
2015	Steven Shafer	Larry Lesko	Marc Lavielle
2014	Stephen Duffull	Richard Lalonde	William Gillespie
2013	France Mentré	Hartmut Derendorf	Jeffery Barrett
2011	Don Rubin	William Jusko	Marc R. Gastonguay
2009	Mats Karlsson	David D'Argenio	
2008	Carl Peck		

	ISoP Technical Manuscript Award	Emerging Scientist Award	Unsung Hero Award
2023	Vidya Ramakrishnan	Peter Bloomingdale & Marissa Renardy	Saroja Ramanujan Manuel Ibarra
2022	Emmanuel Chigutsa et al		Kimberly Adams, Leticia Arrington, Patrick Hanafin & Yi Ting (Kayla) Lien
2021	Tong Lu, Yujie Yang, Jin Y. Jin, and Matts Kågedal	Gopichand Gottipa	
2020	Aman P. Singh et al	Christopher Rackaukas	Michelle Johnson, Mark Lovern & Songmao (Ben) Zheng
2019	Weirong Wang and Donald L. Heald	Elin Svensson	Navin Goyal, Michael Heathman & Kenta Yoshida
2018	Anne – Gaelle Dosne		
2017	Nidal Al-Huniti		

Sameed Ahmed, et al
A novel PBPK/PD model of preclinical data projects the human pharmacologically active dose of a Biologic that modulates immunosuppressive immune cells in the tumor microenvironment
Poster T-005

Robert Parker, et al
Model Predictive Control Regulates Blood Pressure During Simulated Kidney Replacement Therapy
Poster T-097

Anna Kondic, et al
A novel model for Platelets Dynamics: a pragmatic systems approach to characterize thrombocytopenia across multiple compounds and drug classes
Poster T-070

ACoP2024 TRAINEE AWARD WINNERS

Xuefen Yin, et al
Potential Bias Evaluation of Conventional Exposure-Response Analysis Methods: A Small Molecule Cancer Drug Example
Poster T-135

Abdelrahman Saqr, et al
Incorporating High Dimensional Gut Microbiome Data into Population Pharmacokinetic Modeling of Mycophenolate Mofetil
Poster W-108

Sooyoung Lee, et al
Exploring Appropriate Prior Distributions for Covariance Matrix Estimation in Bayesian Population Pharmacokinetic Analysis
Poster W-069

ISoP STATISTICS AND PHARMACOMETRICS SIG TRAINEE AWARD

Parsshava Mehta, et al The Influence of Systematic and Technical Errors on Population Pharmacokinetic/Pharmacodynamic Model Parameters: Nonlinear Mixed-Effect Approach.
Poster W-085

ISoP CLINICAL PHARMACOMETRICS SIG AWARD

Kei Irie, et al Hybrid Population PK-Machine Learning Model Approach to Predict Infliximab Concentrations in Pediatric Patients with Crohn's Disease.
Poster T-057

ISoP QUANTITATIVE SYSTEMS PHARMACOLOGY SIG TRAINEE AWARD

Javiera Cortes, et al Novel computational workflow for selecting virtual patient cohorts for in silico clinical trials
Poster W-018

ISoP MATHEMATICAL AND COMPUTATIONAL SIG AWARD

Jamie Madrigal, et al Mechanistic mathematical model of emicizumab
Poster M-071

ISoP PMX PROGRAMMING SIG AWARD

Philip Delff, et al NMsim: Simulate Nonmem models seamlessly in R without any model reimplementation
Poster T-032

ISoP LEADERSHIP TEAM

Executive Committee
Vijay Ivaturi, President
Kevin Dykstra, President-Elect
C.J. Musante, Immediate Past President
So Miyoshi, Secretary
Wei Gao, Treasurer

Trustees
Amparo de la Peña
Anja Henningsson
Bernd Meibohm
Jeff Sachs
Pavan Vaddady
Hao Zhu

ISoP SPECIAL INTEREST GROUP (SIG) CHAIRS

Clinical Pharmacometrics
(Joint with the American College of Clinical Pharmacology, ACCP)

Yibo Wang, Chair
(Emma) Xizhe Gao, Chair-Elect
Sean Avedissian, Past Chair

Quantitative Systems Pharmacology (QSP)
Lourdes Cucurull-Sanchez, Chair
Anna Georgieva Kondic, Chair-Elect
Ioannis P. Androulakis, Past Chair

Mathematical & Computational Sciences (MCS)
Jiawei Zhou, Chair
Limei Cheng, Chair-Elect
Tongli Zhang, Past Chair

Statistics & Pharmacometrics (SXP)
Tim Waterhouse, Co-Chair, ISoP
Ram Goteti, Co-Chair, ASA
Monica Simeoni, Co-Chair-Elect, ISoP
Luke Fostvedt, Past Co-Chair, ASA

PMx Data Programming
Neelima Thanneer, Co-Chair
Jing Su, Co-Chair

You got this?

Download on iOS or Android

1. Scan the QR code.

2. Install the free Eventscribe app.

3. Open the app and search for ACoP2024.

4. When prompted, log in using your Username and Password *(your Access Key)*.



POSTER SESSION: MONDAY NOVEMBER 11

Poster ID	Presenter	Title
M-001	Brian Adam, Ph.D.	Direct and Indirect Exposure-Response Modeling for Transthyretin Amyloid Cardiomyopathy Treated with Acoramidis
M-002	Sima Ahadieh, Master of Science	A Longitudinal Model-based Meta-Analysis (MBMA) of Body Weight in Obesity Trials
M-003	Jomana Al Hroot	Determining an Appropriate Fosfomycin Dosing Regimen in Pneumonia Patients by Utilizing minimal PBPK Modeling and Target Attainment Analysis
M-004	Mehrdad Javidi	MBMA Bridging Models as A Tool for Exploration of Clinical Endpoints in Unstudied Indications.
M-005	Simon Arsène, Ph.D.	Coupling A Quantitative Systems Pharmacology Model With A Simple Statistical Layer To Predict Asthma Exacerbation Rate Reduction From Allergen Challenge Results
M-006	Simon Arsène, Ph.D.	An innovative paradigm for non-small cell lung cancer clinical trial simulations through the Integration of a quantitative systemic pharmacology model and pharmacodynamic model of gemcitabine
M-007	Simon Arsène, Ph.D.	Leveraging AI for improved reproducibility of mathematical disease models: insights from a retinitis pigmentosa case study
M-008	Simon Arsène, Ph.D.	A within-host dynamic model of Bordetella pertussis to support vaccine development
M-009	Heiko Babel, Ph.D.	Combined multi-analyte population PK modeling of ABBV-400, a novel c-Met targeting ADC
M-010	Dipak Barua	Quantitative system pharmacology model for tri-specific HER2xCD3xCD28 T-Cell Engager SAR443216
M-011	Michael Bewernitz, Ph.D.	A Survey of Model Informed Approaches in Neuroscience Drug Development
M-012	Souvik Bhattacharya	Considerations for Industry—Preparing for the FDA Model-Informed Drug Development (MIDD) Paired Meeting Program
M-013	Clémence Boivin-Champeaux	Development of a quantitative systems pharmacology model for Hepatitis B Virus infection and Hepatitis D virus co-infection.
M-014	Maral Budak, Ph.D.	A systematic efficacy analysis of multidrug therapies for tuberculosis using a multi-scale agent-based model
M-015	Lianjin Cai	Intranasal Diamorphine Population Pharmacokinetics Modeling and Simulation in Pediatric Breakthrough Pain
M-016	Joseph Cave, M.S.	Integrating Physiologically Based Pharmacokinetic Modeling with Machine Learning for the Rational Design of Nanoparticles to Improve Safety in Biomedical Applications
M-017	Li Chen, PharmD	A Semi-mechanistic Pharmacokinetic-Pharmacodynamic/Toxicodynamic Model to Guide Dose Optimization of Combination Therapies Targeting DNA Damage Response Pathways
M-018	Yu Kyoung Cho, Ph.D.	Population Pharmacokinetic Assessment of Guselkumab in Adults with Moderately to Severely Active Ulcerative Colitis
M-019	Kimberly Collins, Ph.D.	Predictors Of Insulin Dose In Individuals With New-Onset Type 1 Diabetes
M-020	Claire Couty	Dissecting Bcl-2 Sensitivity In Acute Myeloid Leukemia: A Quantitative Systems Pharmacology Model For Venetoclax-Azacitidine Therapy
M-021	Claire Couty	Towards A Computational QSP Platform To Support Antibody Drug Conjugate Design In Cancer
M-022	Claire Couty	Towards A QSP Platform To Support Drug Development In Hematological Cancers
M-023	Mackenzie Dalton, M.Sc.	Evaluating the Importance of Glucagon in the Insulin-Glucose Regulatory System: A Mechanistic Modeling Approach
M-024	Oleg Demin Jr, Ph.D.	Mechanistic Translational Modeling Versus Minimal Anticipated Biological Effect Level Approach to Predict First-in-human Dose For T-cell Engagers: HPN536 Case Study.

POSTER SESSION: MONDAY NOVEMBER 11

Poster ID	Presenter	Title
M-025	Sarah DiBartolo	A quantitative systems pharmacology (QSP) model to enable prediction of ARIA-E incidence with anti-Aβ monoclonal antibody therapies for Alzheimer's disease
M-026	Michael G. Dodds, Ph.D.	Augmented Definitive Screening Design Provides Efficient Phase 1 Selection of CAR T-cell and Lymphodepletion Regimen
M-027	Yohei Doi	Model-based meta-analysis of safety for monomethyl auristatin E-conjugated antibody drug conjugates in cancer patients
M-028	Erin Dombrowsky, MSE	A systematic approach for imputing missing dose information in population pharmacokinetic analysis datasets
M-029	Jin Dong, Ph.D.	Bilirubin Elevation Due To Atazanavir Treatment May Primarily Be Mediated By Inhibition Of OATP1B1/3 Rather Than That Of UGT1A1: PBPK Analysis Of Bilirubin-Atazanavir-Polymorphism Interaction
M-030	Lihong Du, Data Sci	A Minimal QSP Model for Treg Responses of IL-2 Mutein MK-6194 – A Conceptual Model for Autoimmune Disease
M-031	Stephen Duffull, Ph.D.	Development and application of a mechanistic model for Alzheimer's Disease
M-032	Xiaoqing Fan, Ph.D.	A Whole-body Mechanistic Physiologically-based Pharmacokinetic Modeling of Intravenous Iron
M-033	Matthew L. Fidler, M.Stat., Ph.D.	babelmixr2 and PopED: Quick Conversion of NONMEM, Monolix and nlmixr2/rxode2 Models to PopED Optimal Design Analysis
M-034	Anna Gaffney, Ph.D.	Population Pharmacokinetic Modeling of Niraparib to Assess Different Absorption Models
W-035	Sharvari Bhagwat, Ph.D.	PK/PD Characterization of INBRX-140, a Novel anti-FcRn x anti-albumin bispecific antibody
M-036	Marc R. Gastonguay, Ph.D., FISoP	Pharmacometric-Pharmacoeconomic Modeling and Simulation in Atopic Dermatitis: Informing Early Drug Development Decisions for a Hypothetical New Therapeutic
M-037	Nathalie H. Gosselin, Ph.D.	K-PD model of Plozasiran in Patients with Severe Hypertriglyceridemia
M-038	Nathalie H. Gosselin, Ph.D.	K-PD Modeling of Plozasiran - Mixed Hyperlipidemia
M-039	Kajal Gupta, M.S.	A PBPK-QSP model for regulation of thyroid hormones in Allan-Herndon Dudley Syndrome
M-040	Izumi Hamada	Novel endpoints based on tumor growth dynamics – A comprehensive simulation study with retrospective validation
M-041	Chihiro Hasegawa, Ph.D.	Exploring Best Practices of the Population Pharmacokinetic Modeling for Antibody-Drug Conjugates – a Simulation Study
M-042	Chihiro Hasegawa, Ph.D.	Model-Informed Dose Justifications and Clinical Pharmacology Strategy of Posaconazole in Japanese Patients for Prophylaxis and Treatment Against Fungal Infection
M-043	Lucy Her, PharmD, Ph.D.	Image Processing with Spatial Modeling of Neural Tissue: A New Approach to Pharmacokinetic Analysis
M-044	Cody Herron, Ph.D.	MIDD Platform of VZV Vaccine Immunogenicity and Efficacy
M-045	Chuanpu Hu, Ph.D.	Visual predictive check of longitudinal models and dropout
M-046	Weize Huang, PharmD. Ph.D.	Development and Application of Inavolisib Physiologically-based Pharmacokinetic (PBPK) Model for Drug-drug Interaction (DDI) Assessment
M-047	Rachel Hudson, M.S., Ph.D.	Population Pharmacokinetics of Nivolumab in Patients with Newly Diagnosed or Relapsed/ Refractory Classical Hodgkin Lymphoma

POSTER SESSION: MONDAY NOVEMBER 11

Poster ID	Presenter	Title
M-048	Jasmine Hughes, Ph.D.	mipdtrial: an open-source R package for simulating model-informed precision dosing trials
M-049	Satyawan B. Jadhav, Ph.D.	Disease Progression Modeling of Stargardt's disease
M-050	Fredrik Jonsson, Ph.D.	Exposure-Response Analysis of Cenobamate
M-051	E. Niclas Jonsson	The impact of misspecified covariate models on inclusion and omission bias when using FREM and FFEM
M-052	Jia Kang, Ph.D.	Accounting For Dose Modifications In Exposure-Response Analyses In Oncology: The Case Example Of Brigimadlin
M-053	Jueun Kang	PKPD modeling and simulation of an inhaled antibiotic targeting Gram-negative bacteria, using a bacteriophage-derived endolysin.
M-054	Georgi Kapitanov, Ph.D.	Preclinical data exposures underpredict clinical physiologically active doses for bispecific TCEs in solid tumors indications; are there better metrics? - insights from a small mechanistic MBMA
M-055	Yushi Kashihara, Ph.D.	Immune Correlates of Protection against Respiratory Syncytial Virus Infection and an Application to Model-Informed Vaccine Development for an internal compound: a Model-Based Meta-Analysis
M-056	Masood Khaksar Toroghi	A Translational Quantitative Systems Pharmacology (QSP) Modeling Framework to Predict Interleukin-15 (IL-15) Cytokine Levels in Multiple Myeloma Patients after Anti-BCMA CAR-NK Cell Therapy
M-057	Richard Khusial, Ph.D.	A Pharmacokinetic Analysis of Drug Concentration Using a Novel Deep Learning Model
M-058	Yoonjin Kim, M.D.	Pharmacokinetic/Pharmacodynamic Modeling for Dose Selection of S-001, a Novel mRNA-based Therapy for Pancreatic Cancer
M-059	Min-Soo Kim, PharmD, Ph.D.	Physiologically based pharmacokinetic (PBPK) modeling of methotrexate in cerebrospinal fluid in humans
M-060	Brandon Klee, PharmD.	Impact of Drug Interactions and Genetic Variability on High-Dose Methotrexate in Children with Acute Lymphoblastic Leukemia
M-061	Luke Kosinski, Ph.D., M.S., M.A.	A clinical trial simulator tool for a randomized delayed start trial in Parkinson's disease
M-062	Shankar Lanke	Successful Dose Optimization and Recommended Phase III Dose Determination of Saruparib (PARP1 Selective Inhibitor) Through MIDD and Comprehensive Quantitative Clinical Pharmacology
M-063	Jaeyeon Lee, Ph.D.	Population Pharmacokinetic/Pharmacodynamic Analysis of YH35995 for the First-in-Human Dose Prediction
M-064	Peizhi Li, PharmD	A semi-mechanistic pharmacometrics model to quantitatively characterize delta-9-tetrahydrocannabinol (THC) and its metabolites' disposition among oral cannabis users
M-065	Laura Liao, Ph.D.	Decoding Mean Viral Load in RSV Human Challenge Studies
M-066	Xiaozhi Liao, B.S. in Pharmaceutical Sciences	Optimizing Clinical Translation of Bispecific T Cell Engagers through Context Unification with a Quantitative Systems Pharmacology Model
M-067	Alan Liu, Ph.D.	Stochastic Simulation and Estimation (SSE) for Design of Sample Size and Time Points in Pediatric Studies
M-068	Dan Lu, Ph.D.	A translational QSP model to characterize the preclinical pharmacodynamics of combining a KRAS G12C inhibitor with a SHP2 inhibitor
M-070	Xiaotang (Jessica) Ma, Ph.D	Model Informed Drug Development (MIDD) Approach to Support Elzovantinib (TPX-022) Recommended Phase 2 Dose

POSTER SESSION: MONDAY NOVEMBER 11

Poster ID	Presenter	Title
M-071	Jamie Madrigal	Mechanistic mathematical model of emicizumab
M-072	Tarunendu Mapder	A shared pool modeling approach to describe antibody-mediated cell-cell interactions
M-073	Andrew Matteson, Ph.D.	A Scalable Cloud-Based QSP Modeling System for Virtual Patient Generation
M-074	Anna Mc Laughlin, Dr. rer. nat.	Exposure-efficacy analysis of datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate, in patients with advanced non-small cell lung cancer
M-075	Sven Mensing	Leveraging Digital Biomarkers to Enhance Clinical Pharmacology and Pharmacometrics Informed Drug Development: A Case Study
M-076	Oleg Milberg, Ph.D.	Methodology of the Exposure-Response (E-R) Analysis of Linvoseltamab in Patients with Relapsed/Refractory (RR) Multiple Myeloma (MM)
M-077	Anita Moein, M.S.	Population Pharmacokinetic Analysis of Fenebrutinib in Patients with Relapsing Multiple Sclerosis
M-078	Krithika Mohan	PKPD Modeling of PROTACs
M-079	Juan F. Morales, Ph.D.	Advancing Drug Development Strategies in Progressive Supranuclear Palsy: A Model-based Clinical Trial Simulation Tool Approach
M-080	Shinji Nakayama	Development of a Simeprevir PBPK Model to Describe Changes in Coproporphyrin-I, an Endogenous OATP1B Biomarker, in Subjects with HCV
M-081	Hoa Nguyen, Ph.D.	Population Pharmacokinetic and Exposure-Response Analyses of Valbenazine in Patients with Huntington's Disease Chorea
M-082	Jing Nie	Integration of pharmacokinetics, safety, and efficacy into model-informed dose selection for Pimicotinib
M-083	Mehdi Nikfar, Ph.D.	Assessing Parameter Impacts on ADC Efficacy and Toxicity: Capabilities and Limitations of Sensitivity Analysis in an Innovative Full Physiologically Based Pharmacokinetic Pharmacodynamic Framework
M-084	Hiroki Okada, MSc	Population Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Analysis of Burosumab in Patients with X-Linked Hypophosphatemia Aged <12 Months
M-085	Hiroki Okada, MSc	PBPK-mQSP Model Analysis of KHK4951, an Eye Drop Formulation of Tivozanib, a Potent and Selective VEGF Receptor Inhibitor
M-086	Olayide A. Oladoyinbo, Ph.D.	Population Pharmacokinetic (Pop PK) Modeling of Nirmatrelvir/Ritonavir in Severe Renal Impaired Participants with COVID-19 either on or not on Hemodialysis
M-087	Mayu Osawa, Ph.D.	Model Platform to Predict Long-Term Clinical Outcome for Patients with Relapsed and Refractory Multiple Myeloma (RRMM)
M-088	John C. Panetta, Ph.D.	Modeling Effects of Dose, Schedule, and Pharmacokinetics of Fludarabine Lymphodepletion Therapy on CAR T-cell and Cytokine Dynamics
M-089	Krutika Patidar	A minimal PBPK model to study the effect of antibody size, charge, and binding affinity to FcRn/antigen on antibody PK
M-090	Arya A. Pourzanjani, Ph.D.	A Novel Approach to Capturing the Dynamics of Nontarget and New Tumors in Mechanistic Models of Progression-Free Survival
M-091	Arya A. Pourzanjani, Ph.D.	Fully Bayesian Covariate Selection in Population Pharmacokinetics and Pharmacodynamics Models Using Regularized Horseshoe Priors
M-092	Prasad Purohit	Integrated Quantitative Systems Pharmacology and Pharmacometric Model to Evaluate Effective Buprenorphine Induction Treatment Strategies in the Era of Synthetic Opioids
M-093	Lauren Quinlan, B.S.	Challenges in curating Real World Data for modeling: A Bronchopulmonary Dysplasia case study

POSTER SESSION: MONDAY NOVEMBER 11

Poster ID	Presenter	Title
M-094	Ousama Rachid, Ph.D.	A Physiological-Based Pharmacokinetic (PBPK) Model embedded with Pulmonary Compartmental Absorption and Transit (PCAT™) Module to Predict Intranasal Ketamine Pharmacokinetics in Pediatric Population
M-095	Vidya Ramakrishnan, Ph.D.	Population Pharmacokinetic Modeling Informed the Dose of GDC-8264 for a Phase 1b Study in Participants with Acute Graft-Versus-Host Disease
M-096	Hyunwook Ryu, PharmD	Population pharmacokinetics analysis of DA-8010, a novel anti-muscarinic agent
M-097	Mark Sale, M.D.	Automatic differentiation, a possible solution to numerical instability in Population PK parameter estimation
M-098	David H. Salinger, Ph.D.	Population pharmacokinetic modeling of TBA-7371 in healthy participants describes apparent auto-induction of clearance and predicts PK of participants with Mycobacterium tuberculosis
M-099	Zeel S. Shah, Ph.D.	Advancing Drug Development in Relapsed and Refractory Multiple Myeloma (RRMM): Assessing the Safety and Efficacy Landscape Utilizing Model-Based Meta-Analysis
M-100	Monica E. Shapiro, Ph.D.	A Quantitative Systems Pharmacology Model of LNP-mRNA Uptake Through LDLR Binding
M-101	Iris Shelly, M.S.	Cardiovascular Model Parameterization of Digital Twins for Acute Care Drug Delivery: An Iterative Bayesian Approach
M-102	Yufei Shi, PharmD	Population Pharmacokinetics and Exposure-Response Analysis of Birociclib Plus Fulvestrant in Advanced Breast Cancer Patients
M-103	Euibeom Shin	Evaluation of ChatGPT and Gemini large language models for pharmacometrics with NONMEM
M-104	Euibeom Shin	Evaluation of prompt engineering strategies for pharmacokinetic data analysis with the ChatGPT large language model
M-105	Melissa Stadt, MMath	Sex differences in patients with chronic kidney disease: A quantitative systems pharmacology modeling study
M-106	Hunter Stephens, Ph.D.	A Model-Informed Drug Development Framework for the Development and Dose Optimization of Targeted Radiation Therapies
M-107	Kefeng Sun, Ph.D.	Physiologically-Based Pharmacokinetic Modeling of Maribavir Incorporating Metabolism by Cytochrome P450, Glucuronidation, and Hepatic Uptake, for Prediction of Victim Drug-Drug Interaction Potentials
M-108	Misako Takenaka, Ph.D.	How should we leverage prior adult knowledge for pediatric PK analysis? - A case study comparing Pooled and Bayesian population PK approaches
M-109	Nessy Tania	Advancing Quantitative Systems Pharmacology Model for Inflammatory Bowel Disease for Clinical Efficacy Predictions in Ulcerative Colitis
M-110	Haryana Yosef Thomas	A quantitative systems pharmacology model for diabetes-induced glomerular fibrosis
M-111	Dominic MH Tong, Ph.D.	Cystatin C complements but does not exceed serum creatinine as a renal function marker: evidence from vancomycin pharmacokinetic model performance in a clinical context
M-112	Junko Toyoshima, Ph.D.	Evaluation of Praziquantel Exposures in Children Dosed Using Different Body Weight Estimation Methods
M-113	Mirjam Trame, Ph.D	Oncology MIDD Simulator, A User-Friendly Application for Overall Survival Forecasting in Early Oncology Trials
M-114	Michael Trogdon, Ph.D.	Virtual clinical trial simulations using a Quantitative Systems Pharmacology (QSP) model of CDK inhibitors in breast cancer patients
M-115	Yuko Umetsu, M.S.	Population Pharmacokinetic and Exposure-Response Analyses of Tasurgratinib in Subjects with Unresectable Advanced or Metastatic Cholangiocarcinoma with Fibroblast Growth Factor Receptor 2 Gene Fusion
M-116	Yuchen Wang, Ph.D.	Approaches of Incorporating Prior Information in Pediatric PopPK Model Development with Limited Data

POSTER SESSION: MONDAY NOVEMBER 11

Poster ID	Presenter	Title
M-117	Angelia F. Wang, Ph.D.	Semi-mechanistic modeling to investigate differential dynamics of anti-citrullinated protein antibody (ACPA) IgG versus total IgG reduction following nipocalimab treatment
M-118	Bonnie Wang, M.S., DABT	Past as Prologue: A Novel Anti-Fucosyl-GM1 Monoclonal Antibody in Extended Stage Small Cell Lung Cancer (ES-SCLC) Phase 3 Dose Selection through Exposure/Dose-Response Analyses of Efficacy and Safety
M-119	Bonnie Wang, M.S., DABT	Population Pharmacokinetic (popPK) of BMS-986012, a Novel Anti-Fucosyl-GM1 Monoclonal Antibody, in Patients with First-Line and Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
M-120	Jeffrey L. Woodhead, Ph.D.	Quantitative Systems Toxicology Modeling of Otenaproxesul Liver Enzyme Elevations Leads to Prediction of Liver Safety for Acute Otenaproxesul Dosing
M-121	Huiming Xia	Population Pharmacokinetics and Exposure-Response Analysis Supports Phase 2 Dose Selection for BMS-986288, a non-fucosylated anti-CTLA4 antibody Prodrug
M-122	Dan Xiao	Overcome the Challenges of NONMEM PopPK Dataset for Late Stage Daily Dose Study
M-123	Christine Xu, Ph.D	Streamlining Dupilumab Nasal Polyposis Clinical Development Strategy: Leveraging Modeling and Biomarker Bridging for the Phase 3 Dose Selection
M-124	Christine Xu, Ph.D	Physiologically-based pharmacokinetic modeling approach to support eliglustat development for pediatric patients with Gaucher disease
M-125	Min Xu	Explore the Impact of Pharmacological Target-Mediated Low Plasma Exposure in Lead Compound Selection in Drug Discovery – a Modeling Approach
M-126	Xiaoyu Yan, Ph.D.	A mechanism-based pharmacokinetic/pharmacodynamic model for iron-regulated hematopoietic stem and progenitor cells commitment towards erythroid and megakaryocyte lineages
M-127	Janice Yang, M.A.	Creating Cell-specific Computational Models of Stem Cell-derived Cardiomyocytes Using Optical Experiments
M-128	Tae Eun Yang, Ph.D.	Population Pharmacokinetic Analysis of Guselkumab in Adults with Moderately to Severely Active Crohn's Disease
M-129	Xinxin Yang, PharmD	Automating Translational Physiologically Based Pharmacokinetic Modeling with R and Simcyp: An Innovative Approach
M-130	Ruihong Yu, Ph.D.	Across-species meta-analysis of methylprednisolone reversible metabolism and pharmacokinetics utilizing allometric and scaling model approaches
M-131	Ruihong Yu, Ph.D.	Physiologically based pharmacokinetic modeling the reversible metabolism and tissue-specific partitioning of methylprednisolone and methylprednisone in rats
M-132	Dongfen Yuan, Ph.D.	Population Pharmacokinetics and Exposure-Response Relationship of Amivantamab in Combination with Carboplatin-Pemetrexed: Analyses from PAPILLON Supporting the Weight-Tiered Q3W Regimen
M-133	Xuanzhen Yuan, M.S.	Utilizing Opportunistic Clinical Study and Population-Based Pharmacometric Models to Identify Rational Empiric Dosing Regimens for Piperacillin-Tazobactam in Critically Ill Patients
M-134	Xianwei Zhang, Ph.D.	A Minimal Physiology-based Pharmacokinetics Model of Blood-Brain Barrier Transport for Monoclonal Antibodies Targeting the Transferrin Receptor
M-135	Yi Zhang, Ph.D.	A Bayesian disease progression model for Major Depressive Disorder
M-136	Yi Zhang, Ph.D.	A time-to-event model for Bronchopulmonary dysplasia based on real-world data
M-137	Janet Zhao	A Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Model for Covalent Bruton Tyrosine Kinase Inhibitor TL-895
M-138	Xirong Zheng	Population cellular kinetics of idecabtagene vicleucel in patients with triple-class-exposed relapsed/refractory multiple myeloma
M-139	Xirong Zheng	Longitudinal modeling of a mechanism-based biomarker informs selection of golcadomide doses and dosing schedules for optimization in patients with relapsed or refractory non-Hodgkin lymphoma

POSTER SESSION: MONDAY NOVEMBER 11

Poster ID	Presenter	Title
M-140	Jessie Zhou	Nipocalimab pharmacokinetic/pharmacodynamic and exposure-response modeling in pregnancies at risk for early-onset severe (EOS) HDFN
M-141	Jiawei Zhou, Ph.D.	Population joint modeling of SARS-CoV-2 neutralizing titer dynamics after COVID-19 mRNA vaccine booster administration
M-142	Rui Zhu, Ph.D.	Evaluating concomitant medication use in cystic fibrosis patients using real-world data (RWD) to inform drug-drug interaction risk assessment and clinical trial design of GDC-6988

POSTER SESSION: TUESDAY NOVEMBER 12

Poster ID	Presenter	Title
T-001	Mai Abdelmageed, B. Pharm, M.Sc., Ph.D.	A Model-based Pharmacokinetic Simulation Tool to Aid Dose Selection of Antisense Oligonucleotides Administered Intrathecally in Pediatrics
T-002	Ruth E. Abrams, Ph.D.	Representation of antibodies is key to generate a predictive vaccine quantitative systems pharmacology (QSP) model
T-005	Sameed Ahmed, Ph.D.	A novel PBPK/PD model of preclinical data projects the human pharmacologically active dose of a Biologic that modulates immunosuppressive immune cells in the tumor microenvironment
T-006	Sulafa Al Sahlawi, PharmD, M.Sc.	Inhibitory Potential of Cannabidiol on Major CYP450s Enzymes: Insights from Physiological-based Pharmacokinetic Modeling
T-007	Michael Attah, PharmD, M.Sc.	Population Pharmacokinetics of Enoxaparin in Neonates and Infants
T-008	Vivaswath S. Ayyar, Ph.D.	Quantitative Systems Pharmacology (QSP) model for combined targeting of BAFF and CD40 pathways in systemic lupus erythematosus
T-009	Dinesh B. Bedathuru	Development of QSP platform model for predicting clinical efficacy and CRS incidence of CD3 bispecifics in STEAP1 Prostate Cancer
T-010	Dinesh B. Bedathuru	A quantitative systems pharmacology model framework for combined clinical efficacy and hematological toxicity predictions for antibody drug conjugates
T-011	Brendan Bender, M.Sc., Ph.D.	A multi-stage modeling approach towards predicting cytokine release syndrome (CRS) in patients receiving Mosunetuzumab
T-012	Corey J. Bishop, Ph.D.	popPK & ER analysis of amivantamab in combination with chemotherapy for the treatment of patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer after osimertinib failure
T-013	Maitreyee Bose, Ph.D.	A hybrid semi-mechanistic and machine learning framework to predict Cytokine Release Syndrome following T-cell engaging immunotherapies
T-014	Emily Bozenhardt, DrPH	Longitudinal Population Pharmacokinetic/Pharmacodynamic Modeling of Continuous Efficacy Endpoint and Biomarker for a Novel Compound
T-015	Nathaniel Braniff, Ph.D.	A quantitative systems pharmacology model to explore resistance mechanisms and combination strategies in ALK+ NSCLC targeted therapies
T-016	Francesco Brizzi, Ph.D.	Bridging the Gap: A Comprehensive Checklist for Hybrid Pharmacometrics-Machine Learning Model Building to Support Oncology Clinical Development
T-017	Fulden Buyukozturk, Ph.D.	Application of an advanced gut PBPK model to characterize intestinal transport and P-glycoprotein-mediated drug-drug interaction: a case study with Digoxin and Clarithromycin
T-018	Youfang Cao, Ph.D.	A Neuro-Dynamic Quantitative Systems Pharmacology (QSP) Model to Describe Pathophysiology of Alzheimer's Disease and Inform Drug Development
T-019	Simone Cassani	Simulate modified Nonmem models using NMsim

POSTER SESSION: TUESDAY NOVEMBER 12

Poster ID	Presenter	Title
T-020	Hwa Jun Cha	Zolpidemsim: A Web-Application for Simulating Pharmacokinetics of Zolpidem
T-021	Danna Chan, M.S., PharmD	Semi-physiological population pharmacokinetic (PPK) model using dose optimization data for ASTX030, an oral fixed-dose combination (FDC) of CDA inhibitor cedazuridine and azacitidine in MDS patients
T-022	Yi Chien Chang	Comparing the Efficacy of Various Insulin Types: A Pharmacokinetic and Pharmacodynamic Modeling Study in Healthy Volunteers
T-023	Min Chen, Master of pharmacy	Cost-effectiveness of paliperidone palmitate long-acting injectables for the treatment of schizophrenic patients: a joint pharmacometric/pharmacoeconomic approach
T-024	Po-Wei Chen, Ph.D.	A Bayesian Approach to Item Response Theory Modeling for Exposure-Response Relationships in Stan
T-025	ChunFu Cheng	Meta-Analysis of Levamisole Pharmacokinetics Across Diverse Species
T-026	Jason Chittenden	A Semi-Mechanistic Population Pharmacokinetic (PopPK) Model of Linvoseltamab With Considerations of Disease-Related Factors in Patients (Pts) with Relapsed/refractory (RR) Multiple Myeloma (MM)
T-027	Suein Choi, M.D., Ph.D.	Integrated Microphysiological System and PBPK Modeling for Prediction of Human Diclofenac Pharmacokinetics
T-028	Francois P. Combes, Ph.D., PharmD	Pooled population PK of alpelisib in patients with PIK3CA-related overgrowth spectrum and breast cancer
T-029	Zihan Cui, Ph.D.	An R-based workflow for clinical trial simulation tool with application in type 1 diabetes studies
T-030	Angelica Davenport	Integration of Temporal Single-Cell RNA Sequencing Data into Quantitative Systems Pharmacology Model of T Cell Differentiation
T-031	An Dela, Ph.D.	Comparison of Sensitivity Analysis Methods in the Context of a QSP Model for Gout
T-032	Philip Delff, Ph.D.	NMsim: Simulate Nonmem models seamlessly in R without any model reimplementation
T-033	Devam A. Desai, M.S.	A translational one pore and two pore whole body physiologically based pharmacokinetic model for ASOs, and siRNA-based therapeutics
T-034	Prashant Dogra, Ph.D.	Translational modeling identifies synergistic combinations of anti-microRNA-155 with standard-of-care drugs in non-small-cell lung cancer
T-035	Prashant Dogra, Ph.D.	Identifying Determinants of Vaccine Efficacy: A Mechanistic Modeling Approach
T-036	Shengnan Du	A Novel Empirical Drug Induced Autoinduction Model to Characterize the Population Pharmacokinetics of Repotrectinib with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
T-037	Shengnan Du	Exposure-Response Efficacy and Safety Analysis of Repotrectinib to Support the Dose Recommendation for Patients with ROS1-positive NSCLC
T-038	Ruihu Du	The PK-PD model of dexamethasone for fetal lung maturation and developmental neurotoxicity: A dose optimization study
T-039	Ahmed Elmokadem, Ph.D.	Symbolic PBPK-PDE Modeling Using Open-Source Julia Tools
T-040	Ahmed Elmokadem, Ph.D.	How to Make a Salad? Rethinking Pharmacometric/QSP Model Composition Using Open-Source Julia Tools
T-041	Fanny Gallais, Ph.D.	Bimekizumab population pharmacokinetic and exposure-response analyses in adults with moderate to severe hidradenitis suppurativa
T-042	Francois Gaudreault, Ph.D.	Use of Model-informed Drug Development and Natural History Data to Inform the Development of Iluzanebart in ALSP: A Neurological Rare Disease

POSTER SESSION: TUESDAY NOVEMBER 12

Poster ID	Presenter	Title
T-043	Anthony Gebhart	Advancing Drug Development through Enhanced Exposure-Response Analysis: The R-Shiny App ERpmx
T-044	Hamidreza Gharahi, Ph.D.	A translational quantitative systems pharmacology modeling framework for FcRn antagonist therapy for myasthenia gravis
T-045	Sungwoo Goo	Mixed effect state space model application for data driven pharmacometrics modeling
T-046	Toufigh Gordi, Ph.D.	A Mixed-effect Pharmacokinetic Model of R835, a Novel Dual IRAK1/4, in Healthy Volunteers After Administration of the Prodrug R289
T-047	Oleg Demin Jr, Ph.D.	FIVEDB as a tool for analysis of in vitro experimental data: cytokine production by primary cells and cell lines
T-048	Eric Greenwald, Ph.D.	App-based in vitro pharmacokinetic driver identification and in silico clinical trial assessment of pharmacokinetic driver models
T-049	Boris Grinshpun, Ph.D.	Building Automated Pharmacometrics Analysis Workflows in R with NMsim
T-050	Stephan Schaller, Ph.D.	A review of OSP suite PBBM capabilities: looking ahead
T-051	Paridhi Gupta	Mechanistic model-based analysis of Total IgG kinetics and pathogenic autoantibody pharmacodynamics in autoimmune diseases
T-052	Paridhi Gupta	Modeling the Time-Varying Impact of Anti-Drug Antibody Formation on the Pharmacokinetics of a Human Monoclonal Antibody in a Preclinical Study
T-053	Min Hai, M.S.	Modeling and inter-species scaling of plasma DHO as a biomarker to inform first-in-human dose selection for a novel DHODH inhibitor
T-054	Michael Heathman, M.S.	The effect of CYP2B6 genotype on the clearance and autoinduction of efavirenz in healthy subjects and the subsequent impact on efavirenz exposure.
T-055	Maud Hennion	Population PK model on preclinical data for optimization of further clinical trial designs in oncology
T-056	Andrew C. Hooker, Ph.D.	A modified Bayesian information criterion (mBIC) with multiple testing correction for population pharmacokinetic model building
T-057	Kei Irie	Hybrid Population PK-Machine Learning Model Approach to Predict Infliximab Concentrations in Pediatric Patients with Crohn's Disease
T-058	Jihyun Jeon	Exposure-response (E-R) relationship between PD-L1 recombinant monoclonal antibody IMC-001 in relapsed or refractory extranodal NK/T cell lymphoma nasal type patients
T-059	Jiyeon Jeon, PharmD	Population Pharmacokinetic Approach to Evaluate Current Recommended Dose of Tacrolimus on Korean Pediatric Liver Transplant Patients
T-060	Jingcheng Chen	AI-Driven Innovative Platform in Quantitative Pharmacology: Literature Insights and Automated Model Construction
T-061	Carter Johnson, Ph.D.	Impact of PD-L2 on Relative Efficacy of Anti-PD-1 and Anti-PD-L1 Antibodies: Insights From QSP-Based Meta-Analysis
T-062	Louis Joslyn, Ph.D.	A Pharmacologically-informed Neural Ordinary Differential Equation Framework to Predict Preclinical Pharmacokinetics
T-063	Jatinder Kaur Mukker, Ph.D.	Advancing Modeling of Hematologic Safety using a Semi-mechanistic Multivariate PK/PD Approach: Application to the ATR Inhibitor Tuvusertib in Early Phase Oncology Development
T-064	Felipe K. Hurtado, Ph.D.	Pharmacokinetic-pharmacodynamic analysis of myelosuppression with raludotatug deruxtecan (R-DXd) in patients with advanced solid tumors

POSTER SESSION: TUESDAY NOVEMBER 12

Poster ID	Presenter	Title
T-065	Zackary R. Kenz, Ph.D.	Weight Loss and Nausea from Subcutaneous and Oral Semaglutide Accurately Simulated with a QSP Model
T-066	Adrian Khoei, PharmD, M.S.	A Novel Concentration-Based Time-Imputation Algorithm for Large Cohort Studies Missing Time-After-Dose Data for Stored Samples
T-067	Dong hyun Kim, Pharm.D	A quantitative systems pharmacology-physiologically based pharmacokinetic model-guided antibiotics regimen design for the treatment of sepsis and septic shock patients
T-068	Kyeongmin Kim, PharmD, M.S.	An integrated model of catabolic clearance mechanisms driving exposure-response confounding for immunotherapies in cancer: interactions between mAb drugs, Fc receptors, and endogenous serum proteins
T-069	Hyeon Ji Kim, PharmD	Assessment of Disease Similarity among Different Racial and/or Ethnic Groups in Oncology: ABC Framework
T-070	Anna Kondic, Ph.D., MBA	A novel model for Platelets Dynamics: a pragmatic systems approach to characterize thrombocytopenia across multiple compounds and drug classes
T-071	Niklas Korsbo, Ph.D.	A Framework for Evaluating Predictive Models Using Synthetic Image Covariates and Longitudinal Data
T-072	Mita Kuchimanchi, M.S.	Exposure–Response Relationship of Dostarlimab With Chemotherapy in Primary Advanced/Recurrent Endometrial Cancer: Results From Interim Analysis Two of Part 1 of ENGOT-EN6-NSGO/GOG-3031/RUBY Trial
T-073	Alexander Kulesza, Ph.D.	Bispecific T-cell engagers and cytokine release syndrome: Modeling molecule, indication and patient-specific aspects
T-074	Ansu Kumar, M.Sc.	Risk Assessment for Drug-Induced Hyperbilirubinemia: A Mechanistic Approach
T-075	Dongjin Lee, Ph.D.	Enhancing Parameter Estimation Process for Pharmacokinetic-Pharmacodynamic Models with Meta-heuristic Optimization Approaches
T-076	Heekyung Lee, Ph.D.	Population Pharmacokinetic-Pharmacodynamic Modeling for Triapine to Optimize Dosing Regimen
T-077	Yuezhe Li, Ph.D.	Quantitative Systems Pharmacology Modeling of Loncastuximab Tesirine Combined with Mosunetuzumab and Glofitamab Helps Guide Dosing for Patients with DLBCL
T-078	Yisheng Li, Ph.D.	A Bayesian Semi-Mechanistic Dose-Finding Design for Phase I Drug Combination Trials in Oncology
T-079	Kathryn G. Link, Ph.D.	A mechanistic QSP model of CRS allows for quantitative assessment of dose priming of CD3 bispecific antibody (BsAb) therapeutics.
T-080	Huan Liu, B.Sc.	A phase I open-label sequential clinical trial and population oral minimal model to study pharmacodynamic interactions of dorzagliatin and empagliflozin in patients with type 2 diabetes and obesity
T-081	Yasong Lu, Ph.D.	Application of Model Informed Drug Development (MIDD) to BT8009, a Bicycle Toxin Conjugate (BTC®), in Patients with Advanced Urothelial Cancer
T-082	Annie Lumen, Ph.D.	Optimizing Clinical Dosing Strategies to Mitigate Corneal Toxicity: Ocular PBPK Model-Based Evaluation of the Extent and Rate of Therapeutic Protein Distribution in the Human Cornea
T-083	Huilin Ma, Ph.D.	Application of quantitative systems pharmacology modeling in reverse translation
T-084	Autumn McKnite, Ph.D.	A combined ex vivo and physiologically-based pharmacokinetic approach to incorporate drug-drug interactions for dosing during continuous renal replacement therapy
T-085	Cameron Meaney, Ph.D.	Modeling progression and treatment of mCRPC using the Thales QSP software platform
T-086	Kenji Miyazawa, Ph.D.	Development of a Whole-Body Physiologically Based Pharmacokinetics (PBPK) Model for Predicting Dynamics of mRNA and Protein for LNP-Encapsulated mRNA Therapeutics

POSTER SESSION: TUESDAY NOVEMBER 12

Poster ID	Presenter	Title
T-087	Ronaldo Morales Junior, Ph.D.	Population pharmacokinetics of cefepime in critically ill children and young adults
T-088	Fereshteh Nazari	A Computational Modeling Framework to Provide a Feasibility Assessment, Inform Competitor Differentiation Strategy, Best-in-Class Properties, and Target Selection for Biologics Targeting IBD
T-089	Christine Neumar, Ph.D.	Integrated Population Pharmacokinetic Model of Bemnifosbuvir and Metabolites
T-090	Chee Meng Ng, PharmD, Ph.D., FCP	Whole-body Two-pore PBPK Model to Investigate the Disposition of Immunoglobulin M (IgM) in Mice
T-091	Chee Meng Ng, PharmD, Ph.D., FCP	Fast Stepwise Selection Methods for Efficient Covariate Model Development in Population Data Analysis
T-092	Emily Nieves	Delineate: a Literature Co-Pilot for Quantitative Systems Pharmacology
T-093	Kumar Kulldeep Niloy	Preclinical tumor growth inhibition modeling and simulation to support dosing regimen selection of a novel EWS-FLI1 inhibitor for Ewing sarcoma treatment
T-094	Takaaki Oka, B.Sc.	Cellular and Humoral Semi-mechanistic Immune Response Models of a Vaccine Candidate for Respiratory Syncytial Virus Infection
T-095	Stefanos Papadopoulos	Modeling the Role of Organ Crosstalk and Cellular Adaptation in Multiple Organ Dysfunction Syndrome
T-096	Alessio Paris	Integrating Motor Function Scores of Spinal Muscular Atrophy in a Quantitative Systems Pharmacology Model of Neurofilament
T-097	Robert Parker, Ph.D.	Model Predictive Control Regulates Blood Pressure During Simulated Kidney Replacement Therapy
T-098	Joseph Piscitelli, PharmD	Population pharmacokinetic modeling of Binimetinib in Healthy Volunteers and Participants with BRAF V600-mutant or NRAS-mutant Solid Tumors
T-099	Bill Poland, Ph.D.	Acoramidis (ALXN2060) Population Pharmacokinetic Modeling and the Importance of Exploring Categorization of Covariate Values
T-100	Satyajit Rao, Ph.D.	Beyond Subcutaneous Dosing: Efficiency of liver-targeting siRNAs dosed via alternates routes and formulations.
T-101	Rohit Rao, Ph.D.	A QSP model of atopic dermatitis to accelerate the clinical translation of novel combination therapies
T-102	Ashley Ray, B.S.	Redefining Multidrug Resistance Quantitatively using Live Cell Functional Data
T-103	Brian Reilly, PharmD, Ph.D.	A model-based simulation workflow enables automated and accurate generation of clinical pharmacology summary statistics, a workflow and case-study.
T-104	Theodore Rieger, Ph.D.	Adaptation of the Glucose, Glucagon, Gastric-Inhibitory Peptide, Glucagon-like Peptide-1, and Insulin (4GI) Model for Simulation of Acute Meal Challenges with Infused Antagonists
T-105	Vrishali S. Salian, M.Sc.	Generating data-driven insights from the Alzheimer's Disease Neuroimaging Initiative (ADNI): Towards establishing a QSP model of Alzheimer's disease
T-106	Conner I. Sandefur, Ph.D.	Simulated CD8+ T Cell-Mediated Liver Injury During Ipilimumab Administration in a Simulated Population (SimPops®) Demonstrates Profiles Consistent with Observed Clinical Data
T-107	Hiroyuki Sayama, Ph.D	Comprehensive Human Quantitative Systems Pharmacology Models for Immuno-Oncology: Enhancing Decision-Making on Target Indications and Combination Strategies for New Drug Development
T-108	Shuai Shao	Comparison of NONMEM and AI-Based Approaches for Population Pharmacokinetic Simulations to Support Model-Informed Drug Development

POSTER SESSION: TUESDAY NOVEMBER 12

Poster ID	Presenter	Title
T-109	Shuai Shao	Model-Based Analysis of Pharmacokinetics of Venglustat, a small-molecule inhibitor of glucosylceramide synthase, Using Pooled Data from Healthy Subjects and Patients with Lysosomal Storage Disorders
T-110	Sanaya Shroff, Ph.D.	Simulation of Trial Predictions with Model Uncertainty using NMsim
T-112	Eric Song, Ph.D.	Application of Machine Learning Methods to Predict Risk of Adverse Events in Clinical Trials
T-113	Phillip Spinosa	QSP model trained on preclinical data informs clinical dose selection for a T-cell engaging bispecific antibody for solid tumor indications
T-114	Prema Sukumar, M.E., B.E.	SAS Macro for Validation of NONMEM Data Items Pertaining to Implicit Expansion of Dose Records in Oral Dose Population Pharmacokinetic Datasets
T-115	Mengdi Tao	Approaches for Developing a Robust Virtual Twin Workflow in Quantitative Systems Pharmacology Models
T-116	Mohamed Tarek, Ph.D.	A DeepNLME-based Tumor Growth Dynamics and Overall Survival Model for Non Small Cell Lung Cancer
T-117	Zachary L. Taylor, Ph.D., M.S.	A High-Dose Methotrexate Dashboard: Integrating MTXPK.org into the Electronic Health Record to Facilitate Model-Informed Care for Pediatric Patients with Malignant Conditions
T-118	Amol V. Tendolkar	Population Pharmacokinetic and Exposure-Response Analyses of Neoadjuvant Nivolumab plus Chemotherapy, followed by Adjuvant Treatment with Nivolumab in Subjects with Resectable Stage II-IIIB NSCLC
T-119	Zhiteng Tian, B.Sc.	Development of a Population Pharmacokinetic Model for Ganciclovir to Assess the Renal Impairment Impact in Chinese Patients
T-120	Hari Prabhath Tummala, PharmD, M.S.	Assessing Sirolimus and Antiretroviral Interactions in People with HIV on Chronic ART: A Population Pharmacokinetic Approach in Non-Transplant Recipients
T-121	Jan-Stefan van der Walt	Joint bi-directional PK-ADA population modelling in immuno-oncology
T-122	Meghna Verma, M.S., Ph.D.	A Quantitative Systems Pharmacology Approach to Understand the Variability of Patient Response to T-cell Bi-specifics in Hematological Malignancies
T-123	Jannik Vollmer, Ph.D.	Monte-Carlo simulations to assess the probability of target attainment for cefepime and enmetazobactam in patients with complicated urinary tract infections
T-124	Jannik Vollmer, Ph.D.	Translational modelling from preclinical data to predict human PK of monoclonal antibodies with engineered FcRn binding
T-125	Ngoc-Anh Thi Vu	Beyond the Michaelis-Menten: Evaluation of Novel IVIVE Approach for Predicting In Vivo Intrinsic Clearance from Hepatocyte Assays
T-126	Guanyu Wang, Ph.D.	Quantification of uncertainty in human dose predictions
T-127	Jin Wang, Ph.D.	Surface plasmon resonance enabled mechanistic pharmacokinetic/pharmacodynamic modeling to support covalent inhibitor drug development: Bruton's tyrosine kinase inhibitor case study
T-128	Qi Wang, Ph.D.	Application of PKPD Principles to Drive the Discovery and Development of Novel BCR-ABL Tyrosine Kinase Inhibitors
T-129	Laura Woo, Ph.D.	A prototype mechanistic systems pharmacology model of Type 2 interventions in eosinophilic esophagitis
T-130	Yujie Wu	Development of the second-generation PBPK model to quantify OATP1B, P-gp, BCRP transporter and CYP3A4 enzyme activity changes for Chinese ESRD patients
T-131	Qiushuang (Rachel) Xu, M.S.	A Bayesian Model-based CTS Tool to Optimize Clinical Trial Design in Duchenne Muscular Dystrophy
T-132	Shuang Xu, Ph.D.	Impacts of dose titration on logistic exposure-response in simulated flexible-dose clinical trials

POSTER SESSION: TUESDAY NOVEMBER 12

Poster ID	Presenter	Title
T-133	Diqin Yan	Placebo Response Model for Alopecia Areata: A Model-based Meta-analysis of Randomized Controlled Trials
T-134	Venkata K. Yellepeddi, Ph.D., RPh, DABCP	Integrating Physiologically Based Pharmacokinetic (PBPK) Modeling and Strain-Specific Exposure-Efficacy Requirements to Refine the Dosage Regimens for Voriconazole in a Pediatric Cancer Population
T-135	Xuefen Yin, M.S.	Potential Bias Evaluation of Conventional Exposure-Response Analysis Methods: A Small Molecule Cancer Drug Example
T-136	Hamim Zahir	Unique Effect of the High-Fat Meal on the Pharmacokinetics of Omaveloxolone Explained by Physiologically Based Biopharmaceutics Modeling
T-137	Xinwen Zhang, Ph.D.	Mechanistic physiologically-based pharmacokinetic platform model to characterize risk of cytochrome P450 based drug-drug interactions for bispecific T cell engagers in oncology patients
T-138	Sihong Zhang	Modeling Patient Risk Factors and their Role in Dose Optimization for Oncological Trials
T-139	Fudan Zheng	Population Pharmacokinetics and Exposure-response Analyses of Amivantamab Administered in Combination with Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Non-Small Cell Lung Cancer
T-140	Rui Zhong	Modeling the frequency of toxicity-induced dose modifications and their impact on conventional exposure-response analysis in targeted therapy
T-141	Jia Zhou, Ph.D.	Model-Based Exploration of the Impact of Prophylactic Tocilizumab on IL-6 Dynamics in Multiple Myeloma Patients Receiving Teclistamab Treatment
T-142	Blessed Winston Arul Dhas, MD	PK-PD modeling of doxycycline, azithromycin, and their combination in treating severe scrub typhus using a general pharmacodynamic interaction (GPDI) model.

POSTER SESSION: WEDNESDAY NOVEMBER 13

Poster ID	Presenter	Title
W-001	Nasrin Afzal	Leveraging quantitative systems pharmacology (QSP) modeling to understand effects of corticosteroids on immune cells and cytokine release following administration of SC Epcoritamab
W-002	Yegwon An	Dual Physiologically-based Pharmacokinetics Models of Nano-Liposomal (Nal-IRI) and Non-Liposomal Irinotecan in Ewing's Family Tumor Xenograft
W-003	Wes Anderson, Ph.D.	Leveraging Machine Learning and Real-World Data: Time-to-Event Analysis of COVID-19 Patients Using Electronic Health Records
W-004	Gaurav Bajaj	Development of QSP model of non-small cell lung cancer and its application to support optimal dose selection for acasunlimab, a bispecific antibody targeting 4-1BB and PD-L1
W-005	Gaurav Bajaj	Utilizing PBPK/RO model for description of GEN1042 (BNT312) PK and prediction of trimer level to guide dose selection
W-006	Gaurav Bajaj	Application of identifiability analysis to obtain reliable parameters of the QSP model describing mechanism of action GEN1042 (BNT312) and acasunlimab
W-007	Kyle Baron, Pharm.D, Ph.D.	Simulating Adaptive Dosing Regimens from PK and PKPD Models Using mrgsolve
W-008	Martin Bergstrand, Ph.D.	The reference corrected VPC (rcVPC) - An informative model diagnostic for assessing underlying exposure-response relationships
W-010	Dean Bottino, Ph.D.	Modeling the evolution of activation marker distributions in flow cytometry data representing cell populations in patients dosed with immunomodulating agents
W-011	Rena Byrne, Ph.D.	Data Gaps, Model Mishaps: Quantifying the Impact of Missing Pharmacometrics Data on Pharmacodynamic Projections

POSTER SESSION: WEDNESDAY NOVEMBER 13

Poster ID	Presenter	Title
W-012	Samuel Castillo, Ph.D.	Reinforcement Learning for Pharmacometrics: A Proof of Concept and Future Directions
W-013	Athanasios Chamzas, M.S.	Patent Ductus Arteriosus in Preterm Infants: Exploring Optimal Acetaminophen Dosing for Oral and Rectal Administration
W-014	Joseph Chen, PharmD	Model-Based Meta Analysis for the IPSOS Trial in Platinum Ineligible NSCLC Patients
W-015	Lara Clemens, Ph.D.	Eculizumab as a Key Comparator for the Evaluation of Complement Targeted Novel Therapeutic Strategies with a QSP Model
W-016	Enoch Cobbina, Ph.D.	Revumenib physiologically based pharmacokinetic model for evaluation of age effect and CYP3A4-mediated drug-drug interaction in relapsed/refractory acute leukemias
W-017	Javiera A. Cortes-Rios, Ph.D.	Integrating mathematical modeling with multiplexed immunofluorescence data to predict drug-induced cell arrest
W-018	Javiera A. Cortes-Rios, Ph.D.	Novel computational workflow for selecting virtual patient cohorts for in silico clinical trials
W-019	Jan de Jong, Ph.D.	Phase 1 Interim Population Pharmacokinetic/Pharmacodynamic Model and Phase 2 Dose Exploration for IMM-1-104, a Novel Concept Oral Deep Cyclic MEK Inhibitor.
W-020	Wilhelmus E.A. De Witte, Ph.D.	In-depth numerical model analysis tools to gain insight into model behavior of large-scale pharmacometric models
W-021	Wilhelmus E.A. De Witte, Ph.D.	Local TMDD of large molecules in tissue interstitial space
W-022	Swati Debroy, Ph.D.	Simulations to Inform Dose Selection for a Phase 2b Trial Investigating TOUR006, a Fully Human Anti-IL6 Antibody, for Treatment of Thyroid Eye Disease
W-023	William S Denney, Ph.D.	Optimized Noncompartmental Half-Life Estimation with Tobit Regression
W-024	Saroj Dhakal	Small molecule exposure prediction (intravenous (IV) and oral (PO)) using Machine learning (ML) in combination with mechanistic modeling.
W-025	Or Dotan, M.A.	Population pharmacokinetic analysis of anti-interleukin-15 monoclonal antibody TEV-53408 in healthy volunteers
W-026	Or Dotan, M.A.	Population pharmacokinetic and pharmacodynamic analysis of natural killer cell levels in response to TEV-53408, an anti-interleukin 15 monoclonal antibody, in healthy volunteers
W-027	Stefanie Drescher, Ph.D.	Population Pharmacokinetic (PopPK) Model to Characterize Pharmacokinetics (PK) of Vepdegestrant, a Proteolysis Targeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, in Healthy Adult Participants
W-028	Seongwon Park, B.S.	Development and application of physiologically based pharmacokinetic model of darunavir on pregnant population
W-029	Johanna Eriksson, Ph.D.	Physiologically based pharmacokinetic modelling to support the development of a sustained-release formulation for the treatment of cryptococcal meningoencephalitis: An MIDD case study
W-030	Yunlan Fang, Ph.D.	Population Pharmacokinetics/Pharmacodynamics Modeling of INCAGN02390 in Patients with Select Advanced Malignancies
W-031	Jeannine M. Fisher, M.S.	Scientific Project Management (SPM) to Enhance Model-Informed Drug Development
W-032	Luke Fostvedt, Ph.D.	Longitudinal Joint Modeling of Modified Mayo Score and Dropout in Patients with Moderate to Severely Active Ulcerative Colitis.
W-033	Christina Friedrich, Ph.D.	Adaptation of a Published Kidney Disease QSP Model to Represent Autosomal-Dominant Polycystic Kidney Disease and Evaluate Treatment Options
W-034	Christina Freidrich, Ph.D.	Parallel Tempering for Generation of Virtual Patients and Virtual Populations

POSTER SESSION: WEDNESDAY NOVEMBER 13

Poster ID	Presenter	Title
W-035	Kapil Gadkar, Ph.D.	Systems model to predict fractional exhaled nitric oxide response to inhaled JAK inhibitors in patients with mild to moderate asthma
W-036	Mohammad Ghasemi, Ph.D.	Population Plasma and Urine Pharmacokinetic Data and Modelling of Casdatifan Supports Administration to Participants with Moderate Renal Impairment
W-037	Juan J. Gonzalez	Evaluation of Large Language Models for an AI Chat Assistant Focused on Pumas and Pharmacometrics
W-038	Malek Hajjawi, PharmD	Development of a Physiologically-Based Pharmacokinetic (PBPK) Model for Caffeine in Pregnancy: Evaluating Neonatal Transfer
W-039	Malek Hajjawi, PharmD	Predictive Pharmacokinetic Analysis of Novel PLCG2 Inhibitors Using GastroPlus and ADMET Predictor
W-040	Nick Henscheid, Ph.D.	Extracting Lab Value Reference Ranges from Neonatal Real-World Data in OMOP Format
W-041	Alejandra Donaji Herrera Reyes, Ph.D.	Inferring HIV rebound timing from a noisy biomarker
W-042	Anhar Hosawi	Population Pharmacokinetic Modeling of Hydroxyurea in Plasma and Breast Milk in Lactating Women
W-043	Hongxiang Hu, Ph.D.	Early sBCMA Kinetics as a Potential Indicator of Progression-Free Survival in Relapsed/Refractory Multiple Myeloma Patients Receiving CAR T-Cell Therapy
W-044	Hongxiang Hu, Ph.D.	Population Cellular Kinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Multiple Myeloma
W-045	Hannah Huang, Ph.D.	Clinical Trial Simulation to Assess Sample Size and Power For Detecting Differences in Pharmacokinetic Exposure Metrics
W-046	Hiroyuki Inoue	Population Pharmacokinetic and Exposure-Response Modelling Analyses to Support Valemetostat Dose Recommendations in Patients With Relapsed/Refractory (R/R) Peripheral T-cell Lymphoma (PTCL)
W-047	Mohamed Ismail, Pharm.D, M.S.	Mechanistic PK/PD modeling of the simultaneous effects of bepirovirsen on hepatitis B surface antigen (HBsAg) and ALT in participants with chronic hepatitis B infection to support Phase 3 study design
W-048	Olga V. Ivanova, Ph.D., MBA	Itacitinib Population Pharmacokinetics (PopPK) and Exposure-Response for Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy: Results From Phase 2 Study NCT04071366
W-049	Tracey Wei, Ph.D.	Exposure-Response Analysis for Hepatotoxicity of Rivoceranib Monotherapy and in Combination with Camrelizumab in Patients with Various Cancers, Including Advanced Hepatocellular Carcinoma
W-050	Praneeth Jarugula, PharmD	Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analysis of Danicamtiv in Heart Failure with Reduced Ejection Fraction
W-051	Priya Jayachandran, PharmD, M.S.E.	Model-based 'learn and confirm approach' demonstrates similarity of cemiplimab exposure in pediatric and adult populations
W-052	Weihua Jiang	Hybrid Minimal Physiological-Based Pharmacokinetic Model of Tenofovir Alafenamide and Its Metabolites Disposition in Humans
W-053	Seongjun Jo	Development of physiologically based pharmacokinetic models for RET inhibitors to predict brain distribution
W-054	Kathleen M. Job, Ph.D.	Effects of sparse sampling in the characterization of leuprolide pharmacokinetics and pharmacodynamics in patients with prostate cancer
W-055	Jordon Johnson, PharmD	Confounding Impact of Event-Driven Exposure Phenomenon on Summary Exposure Metrics in Time-to-Event Exposure Response Analyses

POSTER SESSION: WEDNESDAY NOVEMBER 13

Poster ID	Presenter	Title
W-056	Jordon Johnson, PharmD	Population Pharmacokinetics of Quemliclustat, a Potent, Selective, and Reversible CD73 Inhibitor, in Patients with Cancer
W-057	Ayan K, Research Scientist	Optimizing Drug Development: Assessing Small Language Models for Efficient Drug-Drug Interaction Data Extraction
W-058	Chanchala Kaddi, Ph.D.	QSP-based virtual twin approach provides mechanistic insight into enzyme replacement therapies in Pompe Disease
W-059	Alexander Ratushny	Facilitating RP2D decisions for CAR T cell therapy clinical studies using QSP model
W-060	Oleg Demin Jr, Ph.D.	Quantitative systems pharmacology model for distinguishing efficacy of anti-CD20 therapy variants in populations of Multiple Sclerosis patients
W-061	Oleg Demin Jr, Ph.D.	Quantitative systems pharmacology modeling of neurotoxicity and cognitive scores in Alzheimer's disease for prediction of therapy outcomes
W-062	Juyoung Khwarg, PharmD	Semi-Physiologic Population Pharmacokinetic Model To Evaluate The Effect Of Hepatic-Uptake Transporter Gene Slc22a1 Polymorphism On Pharmacokinetics Of Proguanil And Its Metabolite, Cycloguanil
W-063	Se Jin Kim, PharmD	Cell-line Specific Network Modeling to Assess Differential Signal Transduction of Oxaliplatin-based Drug Combinations for Colorectal Cancer
W-064	Hyeonsu Kim	Comparative evaluation of different vancomycin population pharmacokinetic models to predict Bayesian-estimated vancomycin AUC in Korean patients
W-065	Chaejin Kim, PharmD, MPH, Ph.D.	Extrapolation of Efficacy and Simplification and Optimization of Pediatric Clinical Trial Design for Azilsartan Medoxomil (Edarbi) through Modeling and Simulation
W-066	Jeanne Dulie T. Kom Nzia	Physiologically Based Pharmacokinetic Modeling Of Pioglitazone: Evaluating The Effect Of The Cytochrome P450 2c8*2 Single Nucleotide Polymorphism
W-067	Wojciech Krzyzanski	Gauss-Hermite cohort population estimation of dexamethasone pharmacokinetic parameters in pregnant women using blood samples collected at birth
W-068	Larissa Lachi Silva	Dose determination of Lutathera in adolescents via popPK and dosimetry modeling and simulation
W-069	Sooyoung Lee, Ph.D.	Exploring Appropriate Prior Distributions for Covariance Matrix Estimation in Bayesian Population Pharmacokinetic Analysis
W-070	Xizhe Gao	Concentration-QTc Analysis of PF-07220060 in Patients with Advanced Solid Tumors
W-071	Cristhyne León, Ph.D.	Mathematical modeling can help to successfully translate preclinical findings in mice models of asthma into first-in-human trials
W-072	Vladislav Leonov, Ph.D.	Unraveling Major Inflammatory Cytokines Serum Distribution Patterns in Systemic Lupus Erythematosus Patients: Insights from the CYTOCON Database
W-073	Xiaobin Li, M.S.	xplorer: a Flexible Shiny App for Data Visualization, Exploration and Quality Assurance
W-074	Yi Ting (Kayla) Lien, Ph.D.	Exposure-response analyses of GO39932: a Phase Ia/b study of giredestrant in estrogen receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
W-075	Chay Ngee Lim, Ph.D.	Population pharmacokinetic modeling to support dose selection of rimegepant in pediatrics
W-076	Andreas Lindauer, Ph.D.	Interactive Pharmacometric Simulations and Model Exploration with e-Campsis
W-077	Andreas Lindauer, Ph.D.	An Introduction to Campsis: The R-Based Open-Source PK/PD Simulation Suite
W-078	Yuhan Long, B.S., BSChE	Effect of Convenience Sampling on Overall Drug Exposure during Pregnancy

POSTER SESSION: WEDNESDAY NOVEMBER 13

Poster ID	Presenter	Title
W-079	Xintian Lyu, B.S.	Characterizing Pharmacokinetics Effects on Measures of Overall Drug Exposure during Pregnancy
W-080	Alexander MacDonald	Comparison of common methodologies for accounting for IIV for oral bioavailability (F) in the absence of intravenous data
W-081	Andreea Măgălie, Ph.D.	Quantifying dengue natural immunity and probability of disease using serum antibody titers
W-082	Tu H. Mai, Ph.D.	Population Pharmacokinetic and Exposure-Response Analyses of Alectinib and Its Metabolite M4 to Support Dose Selection in Patients with Resected Stage IB - IIIA ALK-Positive Non-Small Cell Lung Cancer
W-083	Molly Zhao, Ph.D.	Model-based Meta-Analysis (MBMA) to Inform Immuotherapy (IO) Treatment Decisions in Metastatic Non-Small Cell Lung Cancer (mNSCLC)
W-084	Ramin Mehrani, Ph.D.	Exploring the feasibility of using AI to identify patient characteristics predictive of histological endpoints in metabolic dysfunction associated steatohepatitis (MASH)
W-085	Parsshava Mehta, PharmD	The Influence of Systematic and Technical Errors on Population Pharmacokinetic / Pharmacodynamic Model Parameters: Nonlinear Mixed-Effect Approach
W-086	Saurabh Modi	Prediction of progression free survival using tumor growth inhibition models: Effect of model uncertainty, inter-individual variability and observational noise on prediction accuracy
W-087	Joo Young Na	Comparison of empirical and physiologically-based modeling approaches to explore mechanisms of drug-drug interaction between abemaciclib and olaparib in a small cohort of patients with ovarian cancer
W-088	Grace O'Brien, M.S.	pmparams: an R Package for Defining and Formatting Parameter Tables in Pharmacometric Modeling
W-089	Elise Oh, PharmD	Modeling Lenacapavir (LEN) Exposure After Daily Oral Administration Alone and in Combination with Bictegravir (BIC) in People with HIV: A Population Pharmacokinetic Approach
W-090	Sanjana S. Parikh	Physiologically Based Pharmacokinetic Model of Vedolizumab in Adult Patients with Inflammatory Bowel Disease
W-091	Hyunseo Park, M.S.	Characterization of the Effect of Biofilm Formation on the Antimicrobial Activity of Tigecycline against M. abscessus using a Hollow Fiber Infection Model and Pharmacokinetic/Pharmacodynamic Modeling
W-092	Taeshin Park, Ph.D.	Incorporating Computational Fluid Dynamic Modeling into Pharmacometrics Models f or Applications to Gene Therapy, Anti-Inflammatory Treatments and Transdermal Patch Drug Delivery
W-093	Seongwon Park, B.S.	Integration of Population Pharmacokinetic Model for Tenofovir Alafenamide by External Evaluation
W-094	Wansu Park, Ph.D.	Population Pharmacokinetic/Pharmacodynamic Analysis of Cemdisiran (ALN-CC5) in Healthy Subjects and Patients with Immunoglobulin A Nephropathy
W-095	Salil Pendse, M.S.	Physiologically Based Pharmacokinetic (PBPK) modeling of hepatic impairment using PK-Sim
W-096	Cesar Pichardo, Ph.D.	Quantitative Systems Pharmacology of T-cell Engagers and Cytokine Release
W-097	Nikhil Pillai	Predicting pharmacokinetic profile of small molecule drugs based on chemical structure using machine learning.
W-098	Kamrine Poels, Ph.D.	Role of quantitative systems pharmacology (QSP) in optimizing elranatamab dosing regimen for relapsed/refractory multiple myeloma
W-099	Victor Poon, M.S.	Constructing a virtual control arm and evaluating operating characteristics using TGI metrics to support go/no-go decisions for single-arm Phase Ib/II combination studies

POSTER SESSION: WEDNESDAY NOVEMBER 13

Poster ID	Presenter	Title
W-100	Abhigyan Ravula	Pharmacometrics-Based Evaluation of Fixed versus Weight-Based Dosing Strategies for Approved Antibody Drug Conjugates (ADC)
W-101	Juliet Rebello	Development of a Population PK model for an inhaled drug
W-102	Michael Reed, Ph.D.	Mathematical optimization of a thrombopoiesis quantitative systems pharmacology (QSP) model
W-103	Gledys Reynaldo Fernandez, Ph.D.	Prediction of the Biological Effect of PEG-rHuEPO Candidates in Chronic Kidney Disease Patients using a Middle-out Translation Approach
W-104	Owen Richfield, Ph.D.	Modeling Endothelial Cell-Targeted Polymeric Nanoparticle Delivery in Renal Glomeruli
W-105	Josiah Ryman, PharmD, Ph.D.	Informing Early Trial Design in Oncology Through Clinical Trial Simulations from Population Pharmacokinetic-Tumor Growth Inhibition Models
W-106	Jeffrey R. Sachs, Sc.B., Sc.M., Ph.D., ACDRS	Comparing Predicted Serotype-specific Vaccine Effectiveness of Pneumococcal Conjugate Vaccines V114 and PCV20 in Children using a novel model-based meta-analysis approach
W-107	Ruslan Salimgareev	Mechanistic Modeling Of Surface Molecule Interactions: Impact Of Methodology On CAR-T Cell Dose Predictions
W-108	Abdelrahman Saqr, M.S.	Incorporating High Dimensional Gut Microbiome Data into Population Pharmacokinetic Modeling of Mycophenolate Mofetil
W-109	Md Shahinuzzaman, Ph.D.	Comparative Analysis of Minimal Physiologically Based Pharmacokinetic (mPBPK) and Traditional Pharmacokinetic (PK) Models in the Context of Quantitative Systems Pharmacology (QSP) for T-cell Engagers
W-110	Jafar Sadik Shaik, Ph.D.	PK/PD Modeling of the Anti-FcRn Monoclonal Antibody Nipocalimab Administered to Healthy Subjects and Participants with Moderate to Severe Active Rheumatoid Arthritis
W-111	Babajide O. Shenkoya, BPharm, M.S.	Pharmacokinetics of Long-Acting Naltrexone in Pregnancy: Insights from Physiologically Based Pharmacokinetic Modeling
W-112	Jian Shi, Ph.D.	Use of Model-Informed Drug Development (MIDD) to Support Dose Selection of Nivolumab in Combination with Ipilimumab in Adolescent Patients with MSI-H/dMMR Metastatic Colorectal Cancer
W-113	Jian Shi, Ph.D.	Population Pharmacokinetic and Exposure-Response Analyses of Nivolumab in Combination with Ipilimumab to Support Dosing Regimen in Subjects with First-Line MSI-H/dMMR Metastatic Colorectal Cancer
W-114	Vijay K. Siripuram	Consideration of Study design aspects in the creation of virtual populations for organ impairment studies: One size may not fit all
W-115	Amira Soliman	Leveraging PBPK modeling to advance spironolactone complex disposition knowledge
W-116	Inmaculada C. Sorribes, Ph.D.	Simultaneous Population PKPD Analysis of Belantamab Mafodotin, Soluble BCMA, and Serum M-Protein in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM)
W-117	Sara Soufsaf	PMXModelStructuR: A Tool for Pharmacometrics Model Visualization in R
W-118	Steven Sun, PharmD	Evaluation of the population pharmacokinetics of pexmetinib in a simultaneous model of two formulations
W-119	Soujanya Sunkaraneni, M.S. Pharm	Population pharmacokinetics of revumenib in patients with relapsed/refractory acute leukemias
W-120	Daisuke Takaichi, M.S.	Quantitative Systems Pharmacology Modeling of X-linked Hypophosphatemia Disease Pathway Normalization to Predict the Impact of Burosumab Treatment on Serum Biomarkers in Adult and Pediatric Patients
W-121	Wen Rui Tan	Model-informed simulations to determine optimal Piperacillin-Tazobactam Dosing regimens in Pediatric Perioperative Care: Effect of body size and renal function

POSTER SESSION: WEDNESDAY NOVEMBER 13

Poster ID	Presenter	Title
W-122	Zoey Tang, Ph.D.	Dual Target-Mediated Drug Disposition Model to Guide the Selection of Starting Dose and Escalation in FTIH Trials for Volrustomig (MEDI5752), a Monovalent Bispecific Antibody Targeting PD-1 and CTLA-4
W-123	Zoey Tang, Ph.D.	Population pharmacokinetic analysis of Dato-DXd, a TROP2-targeting ADC, in NSCLC and HR-positive, HER2-negative breast cancer patients
W-124	Hannah M. Jones, Ph.D.	Real world examples of PBPK impact on CYP3A4 victim DDI drug label content
W-125	Kevin V. Tobin, Ph.D.	Flux-based IVIVC for predicting oxybutynin exposure with and without occlusion of a transdermal gel
W-126	Kevin V. Tobin, Ph.D.	Population Pharmacokinetics of Atomoxetine at Steady-State Dosing for ADHD Treatment in Children and Adolescents
W-127	Xiao Tong, Ph.D.	Population pharmacokinetic and pharmacodynamic modeling of free serum interleukin-15 in response to TEV-53408, an anti-interleukin 15 monoclonal antibody, in healthy volunteers.
W-128	Brittany Tran, PharmD	Population pharmacokinetics and exposure-safety of DS-6157a in patients with advanced gastrointestinal stromal tumor (GIST)
W-129	Cheng Cui, Ph.D.	Frailty phenotype as a sensitive indicator of aging-related Cytochrome P450 3A functional changes Application of dose optimization recommendations for ticagrelor in the Chinese frail older population
W-130	Celeste Vallejo, Ph.D.	Physiologically Based Pharmacokinetic Models for Infliximab, Ipilimumab, and Nivolumab Developed with GastroPlus® to Predict Hepatic Concentrations
W-131	Mike Wan, Ph.D.	Mechanistic modeling to inform T cell engager development for low copy targets
W-132	Bing Wang, Ph.D.	Population Pharmacokinetic Modeling of IMP7068 in Patients with Advanced Solid Tumors
W-133	Matthew Wiens, M.A.	Losing the Forest: Causal Shapley Additive Explanations for Interpretation of Population-Pharmacokinetic models
W-134	Siyan Xu, Ph.D.	Causal directed acyclic graph (DAG) application in exposure-response analyses
W-135	Feng Yang, Ph.D.	PharmaInsight Explorer: Empowering EDA in Clinical Pharmacology and Safety Science
W-136	Todd Yoder, Ph.D.	Gompertz Cure Rate Survival Models with Stan and Brms
W-137	Deok Yong Yoon, PharmD, Ph.D.	Immune thrombocytopenia purpura (ITP) indication extension allowing for administration of Eltrombopag in adult patients who are refractory to 1L-treatment irrespective of time since diagnosis
W-138	Lin Yuan, M.S.	A model-based framework for assessing schedule dependence of therapeutic window for three-drug combinations
W-139	Lin Yuan, M.S.	Design and evaluation of a novel decision metric for estimating Phase 1 Maximum Tolerated Dose
W-140	Lily Zhang, M.S.	Pharmacokinetics Analysis of Serum and Rectal Tissue Concentrations of VRC01 and VRC01LS in People Without HIV in a Phase 1 Clinical Trial (HVTN 116)
W-141	Yuan Zhao, Ph.D.	Disease progression modeling of myositis from real-world data
W-142	Dandan Luo	Population Pharmacokinetics and Exposure-response Analyses of Lazertinib in Combination with Amivantamab as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic NSCLC

★ ★ ★ ★ ★
DIAMOND SPONSOR

CERTARA®

★ ★ ★ ★ ★
DIAMOND SPONSOR

Pfizer

★★★★★
PLATINUM SPONSOR

Every solution to a problem
is a new problem.

– Johann Wolfgang von Goethe

★★★★★
GOLD SPONSOR

GOLD SPONSOR

METRUM RESEARCH GROUP

SimulationsPlus

SILVER SPONSOR

Allucent
Helping bring new therapies to light

AMGEN®

Bristol Myers Squibb

CSL Behring

GILEAD
Creating Possible

★ ★ ★ ★ ★

SILVER SPONSOR

ICON

Johnson&Johnson

Lilly
A MEDICINE COMPANY

MathWorks®

OCCAMS

★ ★ ★ ★ ★

SILVER SPONSOR

PumasAI

sanofi

SecureGen

teva

VERTEX®

★★★★★

BRONZE SPONSOR

LAPP Leiden Advanced PK-PD

NOVARTIS

Pharmetheus®

QuanTx consulting

UF College of Pharmacy UNIVERSITY of FLORIDA

ROSA®

Thank you to all the ISoP/ACoP2024 Sponsors for your support.

EVENT VENUES



★★★★★ EXHIBITORS

A2-Ai

Allucent
Helping bring new therapies to light

AMADOR BIOSCIENCE
A partner for success

CALVAGONE

CERTARA

ePD
Enhanced Pharmacodynamics

esqLABS
WE EMPOWER HEALTH CARE

ICON

InSysBio
QSP Company

IntiQuan

JuliaHub

★★★★★ EXHIBITORS

METRUM
RESEARCH GROUP

MathWorks

nova
IN SILICO

PD-value

Pharmetheus

PumasAI

RES Group

qPharmetra
Better Decisions, Better Medicines

SecureGen

scinteco
SCIENTIFIC IT COMPANY

SimulationsPlus

VANTAGE
RESEARCH

NOTES

BLAZE NEW TRAILS IN PHARMACOMETRICS

SATURDAY OCTOBER 18 – **TUESDAY** OCTOBER 21, 2025

SAVE THE DATE!

ACoP 2025
AMERICAN CONFERENCE ON PHARMACOMETRICS

Gaylord Rockies Hotel & Convention Center
Aurora, Colorado